Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Novavax, Inc. (NVAX)
USD8.33
-0.10 (-1.13%)
US NASDAQ Healthcare Biotechnology
Address
21 Firstfield Road 20878
Gaithersburg, MD, US
Gaithersburg, MD, US
CEO
John Charles Jacobs
Website
novavax.com
IPO
1995-12-05
CIK 1000694 ISIN US6700024010
Also trades on
Frankfurt Stock Exchange · NVV1.F (EUR)
NASDAQ Global Select · NVAX (USD)
Description
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
News Sentiment (7d)
Based on only 2 articles — low confidence
- Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| INTERNATIONAL STEM CELL CORPORATION | ISCO | 2013-06-14 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD8.33
-0.10 (-1.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
2.41
Float Shares
140.21M
Free Float %
86.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.26% | -0.52% | +18.47% | +14.25% | +33.61% | +43.15% | +51.74% | +13.85% | -92.47% | -88.89% | -87.98% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (23 ratings, all time)
Buy
Price Targets & DCF
Current price
8.33
Low
11.00
+32.1%
Consensus
18.00
+116.2%
Median
18.00
+116.2%
High
25.00
+200.3%
Ratings Trend (MoM)
56% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 2 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 2 |
14.50
+74.2%
|
| All Time | 8 |
39.25
+371.5%
|
Quality scores
Altman Z-Score
-4.39
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+64.7% ★ Q1'26: -79.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+306.5% ★ Q1'26: -102.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-37.9% Q1'26: -24.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+41.4% ★ Q1'26: -11.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +9.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+13.7% Q1'26: -8.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.51× ★ Q1'26: -4.78× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2001 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 7 EPS Ana. |
Dec 2027 7 Rev. Ana. 7 EPS Ana. |
Dec 2028 6 Rev. Ana. 6 EPS Ana. |
Dec 2029 5 Rev. Ana. 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
24.07M
est: 23.46M (+2.6%)
|
30.66M
est: 25.96M (+18.1%)
|
36.25M
est: 38.75M (-6.5%)
|
15.35M
est: 15.27M (+0.6%)
|
31.18M
est: 28.77M (+8.4%)
|
34.29M
est: 35.25M (-2.7%)
|
18.66M
est: 11.90M (+56.8%)
|
22.39M
est: 446.35M (-95.0%)
|
197.58M
est: 1.26B (-84.4%)
|
1.60B
est: 2.01B (-20.4%)
|
556.38M
est: 987.67M (-43.7%)
|
682.16M
est: 684.94M (-0.4%)
|
1.12B
est: 1.06B (+5.6%)
|
407.65M
315.90M – 471.14M
-61.7% YoY
|
273.20M
140.71M – 371.96M
-33.0% YoY
|
361.66M
361.66M – 361.66M
+32.4% YoY
|
430.99M
272.61M – 598.34M
+19.2% YoY
|
464.87M
294.04M – 645.37M
+7.9% YoY
|
| EBITDA |
-5.77M
est: -5.67M (-1.8%)
|
-78.37M
est: -55.25M (-41.8%)
|
-150.71M
est: -135.39M (-11.3%)
|
-258.50M
est: -250.43M (-3.2%)
|
-159.88M
est: -19.64M (-714.2%)
|
-162.98M
est: -24.06M (-577.4%)
|
-113.28M
est: -8.12M (-1,294.3%)
|
-398.23M
est: -304.64M (-30.7%)
|
-1.68B
est: -3.89B (+56.8%)
|
-604.71M
est: -4.93B (+87.7%)
|
-487.39M
est: -390.00M (-25.0%)
|
-108.04M
est: -270.46M (+60.1%)
|
492.33M
est: -420.28M (+217.1%)
|
-160.97M
-186.04M – -124.74M
+61.7% YoY
|
-107.88M
-146.88M – -55.56M
+33.0% YoY
|
-142.81M
-142.81M – -142.81M
-32.4% YoY
|
-170.19M
-236.27M – -107.65M
-19.2% YoY
|
-183.56M
-254.84M – -116.11M
-7.9% YoY
|
| EBIT |
-9.26M
est: -8.44M (-9.7%)
|
-82.79M
est: -59.35M (-39.5%)
|
-156.70M
est: -141.43M (-10.8%)
|
-267.00M
est: -260.87M (-2.4%)
|
-169.70M
est: -20.58M (-724.7%)
|
-172.56M
est: -25.21M (-584.4%)
|
-119.08M
est: -8.51M (-1,298.7%)
|
-403.11M
est: -319.23M (-26.3%)
|
-1.69B
est: -3.91B (+56.7%)
|
-633.77M
est: -4.92B (+87.1%)
|
-528.62M
est: -427.13M (-23.8%)
|
-156.54M
est: -296.21M (+47.2%)
|
464.71M
est: -460.29M (+201.0%)
|
-176.29M
-203.75M – -136.61M
+61.7% YoY
|
-118.15M
-160.86M – -60.85M
+33.0% YoY
|
-156.40M
-156.40M – -156.40M
-32.4% YoY
|
-186.38M
-258.76M – -117.89M
-19.2% YoY
|
-201.04M
-279.10M – -127.16M
-7.9% YoY
|
| Net Income |
-9.75M
est: -8.89M (-9.7%)
|
-82.95M
est: -58.67M (-41.4%)
|
-156.94M
est: -141.16M (-11.2%)
|
-279.97M
est: -271.61M (-3.1%)
|
-183.77M
est: -1.89B (+90.3%)
|
-184.75M
est: -1.54B (+88.0%)
|
-130.10M
est: -827.26M (+84.3%)
|
-418.26M
est: -883.72M (+52.7%)
|
-1.74B
est: -4.02B (+56.7%)
|
-657.94M
est: -586.76M (-12.1%)
|
-545.06M
est: -294.33M (-85.2%)
|
-187.50M
est: -209.23M (+10.4%)
|
440.30M
est: 407.70M (+8.0%)
|
-79.31M
-333.62M – 299.10M
-119.5% YoY
|
-43.22M
-60.48M – -12.68M
+45.5% YoY
|
82.88M
-58.50M – 180.03M
+291.8% YoY
|
135.71M
70.88M – 204.22M
+63.7% YoY
|
138.92M
72.55M – 209.04M
+2.4% YoY
|
| SGA |
18.49M
est: 17.04M (+8.5%)
|
19.93M
est: 15.32M (+30.1%)
|
30.84M
est: 28.10M (+9.7%)
|
46.53M
est: 29.44M (+58.0%)
|
34.45M
est: 55.48M (-37.9%)
|
34.41M
est: 67.98M (-49.4%)
|
34.42M
est: 22.96M (+49.9%)
|
145.29M
est: 860.79M (-83.1%)
|
298.36M
est: 518.51M (-42.5%)
|
488.69M
est: 841.83M (-41.9%)
|
468.95M
est: 649.22M (-27.8%)
|
337.19M
est: 450.23M (-25.1%)
|
150.35M
est: 699.63M (-78.5%)
|
267.96M
207.65M – 309.70M
-61.7% YoY
|
179.58M
92.49M – 244.50M
-33.0% YoY
|
237.73M
237.73M – 237.73M
+32.4% YoY
|
283.30M
179.19M – 393.30M
+19.2% YoY
|
305.57M
193.28M – 424.22M
+7.9% YoY
|
| EPS |
-8.60
est: -7.64 (-12.6%)
|
-7.35
est: -2.68 (-174.8%)
|
-11.97
est: -8.82 (-35.8%)
|
-20.68
est: -21.01 (+1.6%)
|
-12.56
est: -12.40 (-1.3%)
|
-9.99
est: -10.15 (+1.6%)
|
-5.40
est: -5.44 (+0.7%)
|
-7.43
est: -5.81 (-28.0%)
|
-23.44
est: -13.70 (-71.1%)
|
-8.42
est: -7.16 (-17.5%)
|
-5.41
est: -2.28 (-137.0%)
|
-1.23
est: -1.33 (+7.2%)
|
2.72
est: 2.23 (+21.7%)
|
-0.53
-1.93 – 1.73
-123.8% YoY
|
-0.18
-0.35 – -0.07
+66.1% YoY
|
0.49
-0.34 – 1.04
+370.1% YoY
|
0.78
0.41 – 1.18
+61.0% YoY
|
0.80
0.42 – 1.21
+2.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-06 | TD Cowen | Hold | Hold | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-01 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-359.25M
OE per share TTM
-2.10
Owner's Yield
-23.51%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
40.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
65
Total invested
145.93M
Insider transactions (90d)
1
Beneficial owners (>5%)
22
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | STATE STREET CORPORATION | 19.97M | 7.36% | — | 19.97M | — | 19.97M | HC | BOSTON, MASSACHUSETTS | 2017-02-08 | ↗ |
| 2 | Edward C. Johnson 3d | 18.87M | 12.76% | — | — | 18.87M | — | IN | Delaware | 2013-02-14 | ↗ |
| 3 | FMR LLC | 18.87M | 12.76% | — | — | 18.87M | — | HC | Delaware | 2013-02-14 | ↗ |
| 4 | Peter Kolchinsky | 13.20M | 9.90% | 13.20M | — | 13.20M | — | IN | Citizenship or Place of Organization | 2012-05-22 | ↗ |
| 5 | RA Capital Management, LLC | 13.20M | 9.90% | 13.20M | — | 13.20M | — | IA | Massachusetts | 2012-05-22 | ↗ |
| 6 | RA Capital Healthcare Fund, L.P. | 7.48M | 5.70% | 7.48M | — | 7.48M | — | PN | Delaware | 2012-05-22 | ↗ |
| 7 | Morgan Stanley | 7.31M | 6.20% | 13.00 | — | — | 7.31M | HC, CO | Delaware. | 2024-02-09 | ↗ |
| 8 | OppenheimerFunds, Inc. | 6.74M | 9.74% | — | 6.74M | — | — | IA | Colorado | 2009-01-27 | ↗ |
| 9 | Oppenheimer Global Opportunities Fund | 6.56M | 9.48% | — | 6.56M | — | — | IA | Colorado | 2009-01-27 | ↗ |
| 10 | 2 | 6.50M | 6.40% | — | 6.50M | — | 6.50M | OO | Republic of Korea | 2023-08-18 | ↗ |
| 11 | The Vanguard Group - 23-1945930 | 5.60M | 8.79% | — | — | 5.47M | 131.5K | IA | Pennsylvania | 2021-02-10 | ↗ |
| 12 | Himanshu H. Shah | 4.55M | 5.28% | 52.5K | 4.55M | 52.5K | 4.55M | IN | — | 2023-04-27 | ↗ |
| 13 | Shah Capital Management | 4.55M | 5.28% | — | 4.55M | — | 4.55M | IA | — | 2023-04-27 | ↗ |
| 14 | 04-2683227 | 4.47M | 3.65% | — | 3.10M | — | — | IA | Massachusetts | 2012-05-10 | ↗ |
| 15 | (1) BlackRock, Inc. | 4.41M | 5.80% | 4.04M | — | 4.41M | — | HC | Delaware | 2022-03-11 | ↗ |
| 16 | (1)Names of reporting persons. BlackRock, Inc. | 4.41M | 5.80% | — | — | — | — | HC | Delaware | 2022-02-08 | ↗ |
| 17 | Shah Capital Opportunity Fund LP | 4.10M | 4.76% | — | 4.10M | — | 4.10M | PN | — | 2023-04-27 | ↗ |
| 18 | Charles B. Ganz | 340.9K | 3.43% | 340.9K | — | 340.9K | — | IN | U.S.A. | 1997-04-30 | ↗ |
| 19 | Ganz Capital Management, Inc. | 340.9K | 3.43% | 340.9K | — | 340.9K | — | IA | Delaware | 1997-04-30 | ↗ |
| 20 | Probitas Advisors, Inc. | — | 0.00% | — | — | — | — | CO | Delaware | 1997-04-30 | ↗ |
| 21 | The Probitas Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 1997-04-30 | ↗ |
| 22 | The Probitas Offshore Fund, L.P. | — | 0.00% | — | — | — | — | PN | Cayman Islands | 1997-04-30 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
65
-203 vs prev Q
New positions
12
Closed positions
188
Increased
27
Reduced
16
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 15.47M +275.8K (+1.8%) | 103.96M -27.8M (-21.1%) | 9.53% +0.151 pp | 0.00% -0.001 pp | USD40.57 -83.4% | 27 qtrs — |
| 2 | SHAH CAPITAL MANAGEMENT | 14.56M +2.7M (+23.3%) | 97.84M -4.6M (-4.5%) | 8.97% +1.677 pp | 18.87% +0.548 pp | USD7.65 -12.2% | 13 qtrs — |
| 3 | BLACKROCK, INC. | 12.90M +128.5K (+1.0%) | 86.70M -24.0M (-21.7%) | 7.95% +0.063 pp | 0.00% -0.001 pp | USD12.25 -45.1% | 6 qtrs — |
| 4 | STATE STREET CORP | 9.52M +2.3M (+32.3%) | 64.00M +1.6M (+2.6%) | 5.87% +1.424 pp | 0.00% +0.000 pp | USD14.41 -53.4% | 27 qtrs — |
| 5 | BANK OF AMERICA CORP /DE/ | 8.29M +5.2M (+167.3%) | 55.71M +28.8M (+107.2%) | 5.11% +3.193 pp | 0.00% +0.002 pp | USD7.34 -8.4% | 27 qtrs — |
| 6 | SANOFI | 6.88M +— (+0.0%) | 46.24M -13.4M (-22.5%) | 4.24% -0.009 pp | 14.90% -8.017 pp | USD8.04 -16.4% | 5 qtrs — |
| 7 | D. E. SHAW & CO., INC. | 5.99M +1.7M (+40.2%) | 40.27M +3.2M (+8.7%) | 3.69% +1.053 pp | 0.02% +0.001 pp | USD9.98 -32.7% | 10 qtrs — |
| 8 | UBS GROUP AG | 4.89M +1.4M (+39.2%) | 32.89M +2.4M (+7.9%) | 3.01% +0.844 pp | 0.01% +0.001 pp | USD7.50 -10.4% | 27 qtrs — |
| 9 | MILLENNIUM MANAGEMENT LLC | 4.47M +2.3M (+110.1%) | 30.04M +11.6M (+62.9%) | 2.75% +1.440 pp | 0.01% +0.005 pp | USD7.78 -13.6% | 27 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 3.72M -70.7K (-1.9%) | 25.01M -7.9M (-23.9%) | 2.29% -0.048 pp | 0.00% -0.001 pp | USD25.11 -73.2% | 27 qtrs — |
| 11 | MORGAN STANLEY | 3.72M +2.6M (+245.4%) | 24.98M +15.7M (+167.7%) | 2.29% +1.626 pp | 0.00% +0.001 pp | USD8.18 -17.8% | 27 qtrs — |
| 12 | GRAHAM CAPITAL MANAGEMENT, L.P. | 2.53M -19.3K (-0.8%) | 17.01M -5.1M (-23.1%) | 1.56% -0.015 pp | 0.41% +0.057 pp | USD6.28 +7.0% | 13 qtrs — |
| 13 | ALLIANZ ASSET MANAGEMENT GMBH | 2.32M +914.4K (+64.9%) | 15.62M +3.4M (+27.8%) | 1.43% +0.561 pp | 0.02% +0.002 pp | USD7.36 -8.7% | 3 qtrs — |
| 14 | NORTHERN TRUST CORP | 1.45M -75.1K (-4.9%) | 9.77M -3.5M (-26.3%) | 0.90% -0.048 pp | 0.00% -0.001 pp | USD20.67 -67.5% | 27 qtrs — |
| 15 | TSP CAPITAL MANAGEMENT GROUP, LLC | 1.39M -10.0K (-0.7%) | 9.33M -2.8M (-23.0%) | 0.86% -0.008 pp | 2.28% -0.965 pp | USD6.43 +4.5% | 25 qtrs — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.34M +3.8K (+0.3%) | 8.97M -2.6M (-22.3%) | 0.82% +0.001 pp | 0.00% 0.000 pp | USD26.65 -74.8% | 27 qtrs — |
| 17 | BARCLAYS PLC | 1.10M +392.7K (+55.3%) | 7.41M -1.6M (-17.3%) | 0.68% +0.241 pp | 0.00% -0.001 pp | USD10.42 -35.5% | 27 qtrs — |
| 18 | GOLDMAN SACHS GROUP INC | 1.09M +301.3K (+38.2%) | 7.33M +485.5K (+7.1%) | 0.67% +0.185 pp | 0.00% +0.000 pp | USD18.65 -64.0% | 27 qtrs — |
| 19 | MONACO ASSET MANAGEMENT SAM | 1.05M +645.0K (+161.3%) | 7.02M +3.6M (+102.5%) | 0.64% +0.397 pp | 1.22% +1.006 pp | USD7.18 -6.4% | 11 qtrs — |
| 20 | SG AMERICAS SECURITIES, LLC | 976.4K +57.7K (+6.3%) | 6.56M -1.4M (-17.6%) | 0.60% +0.034 pp | 0.01% -0.019 pp | USD11.50 -41.6% | 27 qtrs — |
| 21 | MARSHALL WACE, LLP | 929.6K +879.0K (+1,737.4%) | 6.25M +5.8M (+1,324.1%) | 0.57% +0.541 pp | 0.01% +0.005 pp | USD6.83 -1.6% | 2 qtrs — |
| 22 | SCULPTOR CAPITAL LP | 875.6K +— (+0.0%) | 5.88M -1.7M (-22.5%) | 0.54% -0.001 pp | 0.06% -0.029 pp | USD12.02 -44.1% | 13 qtrs — |
| 23 | HRT FINANCIAL LP | 834.2K -411.5K (-33.0%) | 5.61M -5.2M (-48.1%) | 0.51% -0.255 pp | 0.02% -0.022 pp | USD7.52 -10.6% | 4 qtrs — |
| 24 | BANK OF NEW YORK MELLON CORP | 796.3K +307.1K (+62.8%) | 5.35M +1.1M (+26.2%) | 0.49% +0.189 pp | 0.00% +0.000 pp | USD19.46 -65.5% | 27 qtrs — |
| 25 | JANE STREET GROUP, LLC | 686.8K +72.5K (+11.8%) | 4.62M -710.7K (-13.3%) | 0.42% +0.044 pp | 0.00% 0.000 pp | USD11.14 -39.7% | 6 qtrs — |
| 26 | TWO SIGMA INVESTMENTS, LP | 623.8K -78.2K (-11.1%) | 4.19M -1.9M (-31.1%) | 0.38% -0.049 pp | 0.01% -0.003 pp | USD7.16 -6.1% | 7 qtrs — |
| 27 | BNP PARIBAS ARBITRAGE, SNC | 512.9K +474.8K (+1,246.4%) | 3.45M +3.1M (+943.6%) | 0.32% +0.292 pp | 0.00% +0.001 pp | USD6.87 -2.2% | 27 qtrs — |
| 28 | CAPTION MANAGEMENT, LLC | 486.8K +486.8K (+100.0%) | 3.27M +3.3M (+100.0%) | 0.30% +0.300 pp | 0.02% +0.022 pp | USD6.72 +0.0% | 4 qtrs — |
| 29 | BALYASNY ASSET MANAGEMENT L.P. | 482.7K -229.6K (-32.2%) | 3.24M -2.9M (-47.5%) | 0.30% -0.142 pp | 0.00% -0.004 pp | USD7.58 -11.3% | 7 qtrs — |
| 30 | CITADEL ADVISORS LLC | 476.6K -14.3K (-2.9%) | 3.20M -1.1M (-24.7%) | 0.29% -0.009 pp | 0.00% 0.000 pp | USD39.71 -83.1% | 27 qtrs — |
| 31 | GROUP ONE TRADING, L.P. | 474.6K +96.3K (+25.5%) | 3.19M -90.2K (-2.8%) | 0.29% +0.059 pp | 0.01% 0.000 pp | USD6.45 +4.2% | 7 qtrs — |
| 32 | JUMP FINANCIAL, LLC | 467.1K +20.3K (+4.5%) | 3.14M -734.8K (-19.0%) | 0.29% +0.012 pp | 0.04% -0.008 pp | USD8.59 -21.8% | 6 qtrs — |
| 33 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 431.6K -298.3K (-40.9%) | 2.90M -3.4M (-54.2%) | 0.27% -0.185 pp | 0.00% 0.000 pp | USD6.52 +3.1% | 26 qtrs — |
| 34 | FMR LLC | 424.9K +96.3K (+29.3%) | 2.86M +6.3K (+0.2%) | 0.26% +0.059 pp | 0.00% +0.000 pp | USD8.77 -23.4% | 23 qtrs — |
| 35 | CANADA PENSION PLAN INVESTMENT BOARD | 393.7K +14.4K (+3.8%) | 2.65M -642.9K (-19.5%) | 0.24% +0.008 pp | 0.00% -0.001 pp | USD11.58 -42.0% | 6 qtrs — |
| 36 | WALLEYE TRADING LLC | 371.3K -46.7K (-11.2%) | 2.50M -1.1M (-31.2%) | 0.23% -0.029 pp | 0.00% -0.002 pp | USD8.55 -21.4% | 23 qtrs — |
| 37 | POINT72 ASSET MANAGEMENT, L.P. | 353.5K -115.0K (-24.5%) | 2.38M -1.7M (-41.5%) | 0.22% -0.071 pp | 0.00% -0.004 pp | USD6.52 +3.1% | 12 qtrs — |
| 38 | RAFFERTY ASSET MANAGEMENT, LLC | 329.5K +71.0K (+27.5%) | 2.21M -26.9K (-1.2%) | 0.20% +0.043 pp | 0.01% +0.000 pp | USD10.70 -37.2% | 23 qtrs — |
| 39 | NUVEEN, LLC | 328.8K +— (+0.0%) | 2.21M -641.1K (-22.5%) | 0.20% 0.000 pp | 0.00% 0.000 pp | USD6.41 +4.8% | 4 qtrs — |
| 40 | FIRST TRUST ADVISORS LP | 297.3K +102.3K (+52.5%) | 2.00M +307.4K (+18.2%) | 0.18% +0.063 pp | 0.00% +0.000 pp | USD7.74 -13.2% | 5 qtrs — |
| 41 | SWISS NATIONAL BANK | 272.1K -10.5K (-3.7%) | 1.83M -621.6K (-25.4%) | 0.17% -0.007 pp | 0.00% 0.000 pp | USD79.50 -91.5% | 23 qtrs — |
| 42 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 271.1K +271.1K (+100.0%) | 1.82M +1.8M (+100.0%) | 0.17% +0.167 pp | 0.02% +0.020 pp | USD6.72 +0.0% | 1 qtrs NEW |
| 43 | INVESCO LTD. | 259.4K +29.7K (+12.9%) | 1.74M -248.3K (-12.5%) | 0.16% +0.018 pp | 0.00% +0.000 pp | USD9.83 -31.6% | 24 qtrs — |
| 44 | UBS ASSET MANAGEMENT AMERICAS INC | 249.0K -40.7K (-14.0%) | 1.67M -838.3K (-33.4%) | 0.15% -0.025 pp | 0.00% 0.000 pp | USD23.42 -71.3% | 23 qtrs — |
| 45 | WOLVERINE ASSET MANAGEMENT LLC | 223.8K +— (+0.0%) | 1.50M -436.4K (-22.5%) | 0.14% 0.000 pp | 0.01% -0.003 pp | USD8.67 -22.5% | 27 qtrs — |
| 46 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 199.1K +102.9K (+107.1%) | 1.34M +504.3K (+60.5%) | 0.12% +0.063 pp | 0.00% +0.000 pp | USD9.45 -28.9% | 7 qtrs — |
| 47 | FARALLON CAPITAL MANAGEMENT LLC | 195.0K -585.0K (-75.0%) | 1.31M -5.5M (-80.6%) | 0.12% -0.361 pp | 0.01% -0.022 pp | USD8.59 -21.8% | 8 qtrs — |
| 48 | RHUMBLINE ADVISERS | 189.8K -32.3K (-14.6%) | 1.28M -650.2K (-33.8%) | 0.12% -0.020 pp | 0.00% -0.001 pp | USD25.60 -73.8% | 27 qtrs — |
| 49 | EVERSEPT PARTNERS, LP | 181.2K -62.0K (-25.5%) | 1.22M -890.6K (-42.2%) | 0.11% -0.039 pp | 0.06% -0.084 pp | USD8.67 -22.5% | 4 qtrs — |
| 50 | WELLS FARGO & COMPANY/MN | 166.5K -162.7K (-49.4%) | 1.12M -1.7M (-60.8%) | 0.10% -0.101 pp | 0.00% 0.000 pp | USD7.07 -5.0% | 27 qtrs — |
| 51 | ALLIANCEBERNSTEIN L.P. | 163.2K -157.0 (-0.1%) | 1.10M -319.6K (-22.6%) | 0.10% 0.000 pp | 0.00% 0.000 pp | USD20.28 -66.9% | 27 qtrs — |
| 52 | JACOBS LEVY EQUITY MANAGEMENT, INC | 159.0K +41.3K (+35.1%) | 1.07M +48.0K (+4.7%) | 0.10% +0.025 pp | 0.00% +0.000 pp | USD6.41 +4.8% | 3 qtrs — |
| 53 | PRICE T ROWE ASSOCIATES INC /MD/ | 157.9K -33.1K (-17.3%) | 1.06M -595.0K (-35.9%) | 0.10% -0.021 pp | 0.00% 0.000 pp | USD32.23 -79.1% | 23 qtrs — |
| 54 | LEGAL & GENERAL GROUP PLC | 152.2K -3.5K (-2.3%) | 1.02M -327.3K (-24.2%) | 0.09% -0.002 pp | 0.00% 0.000 pp | USD74.99 -91.0% | 27 qtrs — |
| 55 | AQR CAPITAL MANAGEMENT LLC | 146.7K -33.0K (-18.4%) | 986.0K -572.0K (-36.7%) | 0.09% -0.021 pp | 0.00% -0.001 pp | USD8.72 -22.9% | 6 qtrs — |
| 56 | JUPITER ASSET MANAGEMENT LTD | 146.1K +45.5K (+45.2%) | 981.9K +109.7K (+12.6%) | 0.09% +0.028 pp | 0.01% +0.000 pp | USD6.46 +4.0% | 4 qtrs — |
| 57 | ALPS ADVISORS INC | 133.4K +57.7K (+76.1%) | 896.7K +239.9K (+36.5%) | 0.08% +0.035 pp | 0.01% +0.002 pp | USD7.47 -10.0% | 5 qtrs — |
| 58 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 133.4K -132.0 (-0.1%) | 896.5K -261.3K (-22.6%) | 0.08% 0.000 pp | 0.00% 0.000 pp | USD62.13 -89.2% | 27 qtrs — |
| 59 | NEWEDGE WEALTH, LLC | 130.2K -39.8K (-23.4%) | 875.2K -432.1K (-33.1%) | 0.08% -0.025 pp | 0.01% -0.009 pp | USD10.56 -36.4% | 7 qtrs — |
| 60 | PROFUND ADVISORS LLC | 121.7K +65.6K (+117.1%) | 817.8K +331.7K (+68.2%) | 0.08% +0.040 pp | 0.02% +0.009 pp | USD7.47 -10.0% | 12 qtrs — |
| 61 | DEUTSCHE BANK AG\ | 119.9K +4.9K (+4.3%) | 805.9K -191.3K (-19.2%) | 0.07% +0.003 pp | 0.00% 0.000 pp | USD18.79 -64.2% | 27 qtrs — |
| 62 | SKAANA MANAGEMENT L.P. | 119.0K +100.0 (+0.1%) | 799.7K -231.2K (-22.4%) | 0.07% 0.000 pp | 0.26% -0.029 pp | USD11.52 -41.7% | 13 qtrs — |
| 63 | VOLEON CAPITAL MANAGEMENT LP | 118.8K +118.8K (+100.0%) | 798.0K +798.0K (+100.0%) | 0.07% +0.073 pp | 0.02% +0.017 pp | USD6.72 +0.0% | 1 qtrs NEW |
| 64 | ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | 113.6K +6.0K (+5.6%) | 763.5K -169.3K (-18.1%) | 0.07% +0.004 pp | 0.00% -0.001 pp | USD18.32 -63.3% | 23 qtrs — |
| 65 | SCHONFELD STRATEGIC ADVISORS LLC | 110.0K +52.1K (+89.9%) | 739.4K +237.0K (+47.2%) | 0.07% +0.032 pp | 0.00% +0.000 pp | USD7.75 -13.3% | 2 qtrs — |
| 66 | ATOM INVESTORS LP | 108.2K +108.2K (+100.0%) | 726.9K +726.9K (+100.0%) | 0.07% +0.067 pp | 0.06% +0.058 pp | USD6.72 +0.0% | 3 qtrs — |
| 67 | INTECH INVESTMENT MANAGEMENT LLC | 107.3K +15.9K (+17.4%) | 721.1K -71.1K (-9.0%) | 0.07% +0.010 pp | 0.01% -0.001 pp | USD8.36 -19.6% | 6 qtrs — |
| 68 | STRS OHIO | 106.0K +19.4K (+22.4%) | 712.3K -38.5K (-5.1%) | 0.07% +0.012 pp | 0.00% 0.000 pp | USD6.46 +4.0% | 11 qtrs — |
| 69 | VIRTUS INVESTMENT ADVISERS, INC. | 104.0K +41.9K (+67.4%) | 699.0K +160.1K (+29.7%) | 0.06% +0.026 pp | 0.19% +0.036 pp | USD6.51 +3.2% | 4 qtrs — |
| 70 | HEADLANDS TECHNOLOGIES LLC | 100.3K -222.7K (-69.0%) | 673.9K -2.1M (-75.9%) | 0.06% -0.138 pp | 0.06% -0.167 pp | USD7.62 -11.8% | 3 qtrs — |
| 71 | VONTOBEL HOLDING LTD. | 100.0K +37.7K (+60.6%) | 671.7K +132.1K (+24.5%) | 0.06% +0.023 pp | 0.00% +0.001 pp | USD11.68 -42.5% | 21 qtrs — |
| 72 | WALLEYE CAPITAL LLC | 99.9K -52.6K (-34.5%) | 671.3K -650.8K (-49.2%) | 0.06% -0.033 pp | 0.00% -0.003 pp | USD7.49 -10.3% | 8 qtrs — |
| 73 | AQUATIC CAPITAL MANAGEMENT LLC | 98.3K +98.3K (+100.0%) | 660.9K +660.9K (+100.0%) | 0.06% +0.061 pp | 0.02% +0.019 pp | USD6.72 +0.0% | 1 qtrs NEW |
| 74 | FREESTONE GROVE PARTNERS LP | 97.0K +97.0K (+100.0%) | 651.8K +651.8K (+100.0%) | 0.06% +0.060 pp | 0.00% +0.005 pp | USD6.72 +0.0% | 1 qtrs NEW |
| 75 | MARTINGALE ASSET MANAGEMENT L P | 94.8K +105.0 (+0.1%) | 636.8K -183.9K (-22.4%) | 0.06% 0.000 pp | 0.02% -0.005 pp | USD6.70 +0.3% | 11 qtrs — |
| 76 | MITSUBISHI UFJ TRUST & BANKING CORP | 89.2K +55.1K (+161.7%) | 599.3K +303.9K (+102.9%) | 0.05% +0.034 pp | 0.00% +0.001 pp | USD6.56 +2.4% | 3 qtrs — |
| 77 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 88.7K +6.0K (+7.2%) | 596.3K -120.1K (-16.8%) | 0.05% +0.004 pp | 0.00% 0.000 pp | USD11.74 -42.8% | 7 qtrs — |
| 78 | RAYMOND JAMES FINANCIAL INC | 84.1K -3.4K (-3.9%) | 564.9K -193.7K (-25.5%) | 0.05% -0.002 pp | 0.00% 0.000 pp | USD7.18 -6.4% | 5 qtrs — |
| 79 | METLIFE INVESTMENT MANAGEMENT, LLC | 80.5K -10.6K (-11.6%) | 541.2K -248.7K (-31.5%) | 0.05% -0.007 pp | 0.00% -0.001 pp | USD11.67 -42.4% | 16 qtrs — |
| 80 | IMC-CHICAGO, LLC | 78.1K +78.1K (+100.0%) | 524.7K +524.7K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.000 pp | USD6.72 +0.0% | 4 qtrs — |
| 81 | THRIVENT FINANCIAL FOR LUTHERANS | 76.6K +76.6K (+100.0%) | 515.0K +515.0K (+100.0%) | 0.05% +0.047 pp | 0.00% +0.001 pp | USD6.72 +0.0% | 3 qtrs — |
| 82 | JPMORGAN CHASE & CO | 72.2K -813.0 (-1.1%) | 485.2K -147.8K (-23.4%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD47.70 -85.9% | 27 qtrs — |
| 83 | CITIGROUP INC | 69.9K +43.5K (+164.7%) | 469.9K +240.9K (+105.2%) | 0.04% +0.027 pp | 0.00% +0.000 pp | USD9.97 -32.6% | 27 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 101 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Genomics Immunology and Healthcare ETF IDNA | 1.61% | 3.14M | 0.47% |
| 2 | Virtus Biotech ETF BBP | 1.35% | 1.33M | 0.34% |
| 3 | Global X - S&P Biotech ETF CURE.AX | 0.65% | 233.8K | 0.45% |
| 4 | State Street SPDR S&P Biotech ETF XBI | 0.65% | 70.44M | 0.35% |
| 5 | WisdomTree U.S. SmallCap Fund EES | 0.37% | 2.65M | 0.38% |
| 6 | Federated Hermes MDT Small Cap Core ETF FSCC | 0.31% | 505.9K | 0.51% |
| 7 | Barron's 400SM ETF BFOR | 0.20% | 457.1K | 0.65% |
| 8 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.17% | 1.91M | 0.40% |
| 9 | Pacer WealthShield ETF PWS | 0.13% | 32.6K | 0.60% |
| 10 | iShares Biotechnology ETF IBB | 0.11% | 10.56M | 0.44% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
165.5K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+165,500
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-25 | Newton Charles W. | Director | M-Exempt | D | Restricted Stock Units | 9,520 | 0.00 | — | 19,040 | D | ↗ |
| 2026-04-14 | Walker Robert Edward | Officer | A-Award | A | Stock Option (Right to Buy) | 99,500 | 8.46 | 841.8K | 99,500 | D | ↗ |
| 2026-03-10 | Shiver John W. | Director | M-Exempt | D | Restricted Stock Units | 7,947 | 0.00 | — | 15,893 | D | ↗ |
| 2026-03-07 | Kelly James Patrick | Officer | F-InKind | D | Common Stock | 5,904 | 9.98 | 58.9K | 130,599 | D | ↗ |
| 2026-03-03 | O'Hara Elaine | Officer | M-Exempt | D | Restricted Stock Units | 56,334 | 0.00 | — | 112,666 | D | ↗ |
| 2026-03-03 | Kelly James Patrick | Officer | M-Exempt | D | Restricted Stock Units | 43,167 | 0.00 | — | 86,333 | D | ↗ |
| 2026-03-03 | Jacobs John C | Director / Officer | M-Exempt | A | Common Stock | 150,167 | 0.00 | — | 264,130 | D | ↗ |
| 2026-03-03 | Draghia-Akli Ruxandra | Officer | F-InKind | D | Common Stock | 11,313 | 9.49 | 107.4K | 23,563 | D | ↗ |
| 2026-03-03 | Casey Mark J | Officer | M-Exempt | D | Restricted Stock Units | 4,000 | 0.00 | — | 4,000 | D | ↗ |
| 2026-03-02 | O'Hara Elaine | Officer | A-Award | A | 2026 Non-statutory Stock Option NQ | 177,500 | 9.09 | 1.61M | 177,500 | D | ↗ |
| 2026-03-02 | Kelly James Patrick | Officer | A-Award | A | Non-statutory Stock Option NQ | 194,000 | 10.11 | 1.96M | 194,000 | D | ↗ |
| 2026-03-02 | Jacobs John C | Director / Officer | A-Award | A | Non-Statutory Stock Option NQ | 551,500 | 9.09 | 5.01M | 551,500 | D | ↗ |
| 2026-03-02 | Draghia-Akli Ruxandra | Officer | A-Award | A | Non-Statutory Stock Option NQ | 139,500 | 10.11 | 1.41M | 139,500 | D | ↗ |
| 2026-03-02 | Casey Mark J | Officer | A-Award | A | Restricted Stock Units | 101,000 | 0.00 | — | 101,000 | D | ↗ |
| 2026-03-01 | O'Hara Elaine | Officer | M-Exempt | D | Restricted Stock Units | 19,600 | 0.00 | — | 0 | D | ↗ |
| 2026-03-01 | Kelly James Patrick | Officer | D-Return | D | Restricted Stock Units | 58,666 | 0.00 | — | 58,666 | D | ↗ |
| 2026-03-01 | Jacobs John C | Director / Officer | M-Exempt | D | Restricted Stock Units | 83,333 | 0.00 | — | 0 | D | ↗ |
| 2026-03-01 | Casey Mark J | Officer | M-Exempt | A | Common Stock | 4,000 | 0.00 | — | 65,159 | D | ↗ |
| 2026-01-23 | Jacobs John C | Director / Officer | F-InKind | D | Common Stock | 39,132 | 9.17 | 358.8K | 180,797 | D | ↗ |
| 2025-12-11 | Casey Mark J | Officer | F-InKind | D | Common Stock | 12,713 | 6.69 | 85.0K | 61,159 | D | ↗ |
| 2025-11-11 | Draghia-Akli Ruxandra | Officer | D-Return | D | Restricted Stock Units | 14,257 | 0.00 | — | 28,513 | D | ↗ |
| 2025-10-29 | Rodgers Richard J | Director | M-Exempt | A | Common Stock | 3,800 | 0.00 | — | 28,490 | D | ↗ |
| 2025-06-20 | Rodgers Richard J | Director | A-Award | A | Restricted Stock Units | 18,884 | 0.00 | — | 18,884 | D | ↗ |
| 2025-06-20 | MOTT DAVID M | Director | A-Award | A | Restricted Stock Units | 18,884 | 0.00 | — | 18,884 | D | ↗ |
| 2025-06-20 | MCGLYNN MARGARET G | Director | A-Award | A | Stock Option (Right to Buy) | 28,326 | 6.42 | 181.9K | 28,326 | D | ↗ |
| 2025-06-20 | King Rachel K. | Director | A-Award | A | Restricted Stock Units | 18,884 | 0.00 | — | 18,884 | D | ↗ |
| 2025-06-20 | DOUGLAS RICHARD | Director | A-Award | A | Stock Option (Right to Buy) | 28,326 | 6.42 | 181.9K | 28,326 | D | ↗ |
| 2025-06-20 | Alton Gregg H | Director | A-Award | A | Restricted Stock Units | 18,884 | 0.00 | — | 18,884 | D | ↗ |
| 2025-06-12 | Rodgers Richard J | Director | M-Exempt | A | Common Stock | 10,420 | 0.00 | — | 24,690 | D | ↗ |
| 2025-06-12 | MOTT DAVID M | Director | M-Exempt | D | Restricted Stock Units | 10,420 | 0.00 | — | 0 | D | ↗ |
| 2025-06-12 | MCGLYNN MARGARET G | Director | M-Exempt | D | Restricted Stock Units | 10,420 | 0.00 | — | 0 | D | ↗ |
| 2025-06-12 | King Rachel K. | Director | M-Exempt | A | Common Stock | 10,420 | 0.00 | — | 25,190 | D | ↗ |
| 2025-06-12 | DOUGLAS RICHARD | Director | M-Exempt | D | Restricted Stock Units | 10,420 | 0.00 | — | 0 | D | ↗ |
| 2025-06-12 | Alton Gregg H | Director | M-Exempt | D | Restricted Stock Units | 10,420 | 0.00 | — | 0 | D | ↗ |
| 2025-04-25 | Newton Charles W. | Director | A-Award | A | Stock Option (Right to buy) | 42,840 | 6.70 | 287.0K | 42,840 | D | ↗ |
| 2025-03-10 | Shiver John W. | Director | A-Award | A | Restricted Stock Units | 23,840 | 0.00 | — | 23,840 | D | ↗ |
| 2025-03-07 | Trizzino John | Officer | M-Exempt | A | Common Stock | 28,890 | 0.00 | — | 82,015 | D | ↗ |
| 2025-03-07 | Kelly James Patrick | Officer | M-Exempt | D | Restricted Stock Units | 12,223 | 0.00 | — | 12,223 | D | ↗ |
| 2025-03-03 | O'Hara Elaine | Officer | A-Award | A | 2025 Non-statutory Stock Option NQ | 253,500 | 7.87 | 2.00M | 253,500 | D | ↗ |
| 2025-03-03 | Kelly James Patrick | Officer | A-Award | A | 2025 Restricted Stock Units RSU | 129,500 | 0.00 | — | 129,500 | D | ↗ |
| 2025-03-03 | Jacobs John C | Director / Officer | A-Award | A | 2025 Non-statutory Stock Option NQ | 676,000 | 7.87 | 5.32M | 676,000 | D | ↗ |
| 2025-03-03 | Draghia-Akli Ruxandra | Officer | A-Award | A | 2025 Restricted Stock Units RSU | 80,000 | 0.00 | — | 80,000 | D | ↗ |
| 2025-03-03 | Casey Mark J | Officer | A-Award | A | 2025 Restricted Stock Units RSU | 112,500 | 0.00 | — | 112,500 | D | ↗ |
| 2025-03-01 | Trizzino John | Officer | F-InKind | D | Common Stock | 23,185 | 8.33 | 193.1K | 53,125 | D | ↗ |
| 2025-03-01 | O'Hara Elaine | Officer | M-Exempt | D | Restricted Stock Units | 19,600 | 0.00 | — | 19,600 | D | ↗ |
| 2025-03-01 | Kelly James Patrick | Officer | F-InKind | D | Common Stock | 28,337 | 8.33 | 236.0K | 62,932 | D | ↗ |
| 2025-03-01 | Jacobs John C | Director / Officer | M-Exempt | A | Common Stock | 83,334 | 0.00 | — | 175,183 | D | ↗ |
| 2025-03-01 | Casey Mark J | Officer | M-Exempt | D | Restricted Stock Units | 4,000 | 0.00 | — | 8,000 | D | ↗ |
| 2025-01-23 | Jacobs John C | Director / Officer | M-Exempt | A | Common Stock | 83,196 | 0.00 | — | 130,722 | D | ↗ |
| 2024-12-31 | YOUNG JAMES F | Director | S-Sale | D | Common Stock | 5,400 | 8.00 | 43.2K | 51,760 | D | ↗ |
| 2024-12-31 | MCGLYNN MARGARET G | Director | A-Award | A | Common Stock | 1,178 | 8.61 | 10.1K | 15,168 | D | ↗ |
| 2024-12-31 | Kelly James Patrick | Officer | M-Exempt | D | Restricted Stock Units | 35,000 | 0.00 | — | 0 | D | ↗ |
| 2024-12-31 | Alton Gregg H | Director | A-Award | A | Common Stock | 1,982 | 8.61 | 17.1K | 18,385 | D | ↗ |
| 2024-12-24 | YOUNG JAMES F | Director | S-Sale | D | Common Stock | 4,600 | 8.48 | 39.0K | 57,160 | D | ↗ |
| 2024-12-13 | King Rachel K. | Director | S-Sale | D | Common Stock | 4,150 | 9.02 | 37.4K | 14,770 | D | ↗ |
| 2024-12-11 | Casey Mark J | Officer | F-InKind | D | Common Stock | 12,713 | 8.82 | 112.1K | 29,187 | D | ↗ |
| 2024-11-11 | Draghia-Akli Ruxandra | Officer | A-Award | A | Stock Option (Right to Buy) | 64,150 | 9.01 | 578.0K | 64,150 | D | ↗ |
| 2024-10-29 | Rodgers Richard J | Director | M-Exempt | A | Common Stock | 3,800 | 0.00 | — | 14,270 | D | ↗ |
| 2024-09-30 | MCGLYNN MARGARET G | Director | A-Award | A | Common Stock | 778 | 12.77 | 9.9K | 13,990 | D | ↗ |
| 2024-09-30 | Alton Gregg H | Director | A-Award | A | Common Stock | 1,311 | 12.77 | 16.7K | 16,403 | D | ↗ |
| 2024-08-19 | Trizzino John | Officer | F-InKind | D | Common Stock | 317 | 13.90 | 4.4K | 28,310 | — | ↗ |
| 2024-08-16 | Kelly James Patrick | Officer | F-InKind | D | Common Stock | 1,223 | 12.96 | 15.9K | 14,429 | — | ↗ |
| 2024-06-30 | MCGLYNN MARGARET G | Director | A-Award | A | Common Stock | 713 | 13.93 | 9.9K | 13,212 | D | ↗ |
| 2024-06-30 | Alton Gregg H | Director | A-Award | A | Common Stock | 1,202 | 13.93 | 16.7K | 15,092 | D | ↗ |
| 2024-06-21 | YOUNG JAMES F | Director | S-Sale | D | Common Stock | 7,500 | 14.09 | 105.7K | 61,760 | — | ↗ |
| 2024-06-18 | YOUNG JAMES F | Director | S-Sale | D | Common Stock | 6,393 | 13.62 | 87.1K | 70,367 | — | ↗ |
| 2024-06-17 | Dubovsky Filip | Officer | S-Sale | D | Common Stock | 12,500 | 14.46 | 180.8K | 68,017 | — | ↗ |
| 2024-06-12 | YOUNG JAMES F | Director | A-Award | A | Restricted Stock Units | 10,420 | 0.00 | — | 10,420 | — | ↗ |
| 2024-06-12 | Rodgers Richard J | Director | M-Exempt | D | Restricted Stock Units | 6,670 | 0.00 | — | 0 | — | ↗ |
| 2024-06-12 | MOTT DAVID M | Director | M-Exempt | D | Restricted Stock Units | 6,670 | 0.00 | — | 0 | — | ↗ |
| 2024-06-12 | MCGLYNN MARGARET G | Director | M-Exempt | D | Restricted Stock Units | 6,670 | 0.00 | — | 0 | — | ↗ |
| 2024-06-12 | King Rachel K. | Director | A-Award | A | Stock Option (Right to Buy) | 15,630 | 15.86 | 247.9K | 15,630 | — | ↗ |
| 2024-06-12 | DOUGLAS RICHARD | Director | M-Exempt | D | Restricted Stock Units | 6,670 | 0.00 | — | 0 | — | ↗ |
| 2024-06-12 | Alton Gregg H | Director | M-Exempt | D | Restricted Stock Units | 6,670 | 0.00 | — | 0 | — | ↗ |
| 2024-05-14 | Dubovsky Filip | Officer | M-Exempt | D | Stock Option (Right to Buy) | 19,652 | 6.97 | 137.0K | 47,728 | — | ↗ |
| 2024-03-31 | MCGLYNN MARGARET G | Director | A-Award | A | Common Stock | 2,029 | 4.90 | 9.9K | 5,829 | D | ↗ |
| 2024-03-31 | Alton Gregg H | Director | A-Award | A | Common Stock | 3,420 | 4.90 | 16.8K | 7,220 | D | ↗ |
| 2024-03-27 | Dubovsky Filip | Officer | — | D | Stock Option (Right to Buy) | 50,000 | 0.00 | — | 0 | — | ↗ |
| 2024-03-10 | Trizzino John | Officer | M-Exempt | D | Restricted Stock Units | 4,608 | 0.00 | — | 4,608 | — | ↗ |
| 2024-03-10 | Kelly James Patrick | Officer | F-InKind | D | Common Stock | 2,226 | 5.45 | 12.1K | 13,285 | — | ↗ |
| 2024-03-10 | Dubovsky Filip | Officer | M-Exempt | D | Restricted Stock Units | 5,376 | 0.00 | — | 5,376 | — | ↗ |
| 2024-03-07 | Trizzino John | Officer | M-Exempt | A | Common Stock | 28,890 | 0.00 | — | 39,545 | — | ↗ |
| 2024-03-07 | Kelly James Patrick | Officer | M-Exempt | D | Restricted Stock Units | 12,224 | 0.00 | — | 24,446 | — | ↗ |
| 2024-03-07 | Dubovsky Filip | Officer | M-Exempt | D | Restricted Stock Units | 19,444 | 0.00 | — | 0 | — | ↗ |
| 2024-03-01 | Trizzino John | Officer | A-Award | A | Restricted Stock Units | 144,000 | 0.00 | — | 144,000 | — | ↗ |
| 2024-03-01 | O'Hara Elaine | Officer | A-Award | A | Restricted Stock Units | 120,000 | 0.00 | — | 120,000 | — | ↗ |
| 2024-03-01 | Kelly James Patrick | Officer | A-Award | A | Restricted Stock Units | 176,000 | 0.00 | — | 176,000 | — | ↗ |
| 2024-03-01 | Jacobs John C | Director / Officer | A-Award | A | Restricted Stock Units | 250,000 | 0.00 | — | 250,000 | — | ↗ |
| 2024-03-01 | Dubovsky Filip | Officer | A-Award | A | Restricted Stock Units | 144,000 | 0.00 | — | 144,000 | — | ↗ |
| 2024-03-01 | Casey Mark J | Officer | A-Award | A | Restricted Stock Units | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2024-01-23 | Jacobs John C | Director / Officer | M-Exempt | D | Restricted Stock Units | 83,197 | 0.00 | — | 166,393 | — | ↗ |
| 2023-12-14 | Trizzino John | Officer | M-Exempt | D | Restricted Stock Units | 1,600 | 0.00 | — | 0 | — | ↗ |
| 2023-12-14 | Herrmann John A III | Officer | F-InKind | D | Common Stock | 700 | 5.69 | 4.0K | 13,233 | — | ↗ |
| 2023-12-14 | Dubovsky Filip | Officer | F-InKind | D | Common Stock | 1,368 | 5.69 | 7.8K | 53,782 | — | ↗ |
| 2023-12-11 | Casey Mark J | Officer | A-Award | A | Stock Options (Right to buy) | 144,694 | 5.57 | 805.9K | 144,694 | — | ↗ |
| 2023-11-05 | Dubovsky Filip | Officer | F-InKind | D | Common Stock | 677 | 7.06 | 4.8K | 52,317 | — | ↗ |
| 2023-10-29 | Rodgers Richard J | Director | M-Exempt | D | Restricted Stock Units | 3,800 | 0.00 | — | 7,600 | — | ↗ |
| 2023-09-16 | Dubovsky Filip | Officer | M-Exempt | A | Common Stock | 12,644 | 7.71 | 97.5K | 57,702 | — | ↗ |
| 2023-09-12 | Kelly James Patrick | Officer | A-Award | D | Restricted Stock Units | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2023-08-19 | Trizzino John | Officer | M-Exempt | A | Common Stock | 655 | 0.00 | — | 10,145 | — | ↗ |
| 2023-08-16 | Kelly James Patrick | Officer | M-Exempt | D | Restricted Stock Units | 2,366 | 0.00 | — | 2,367 | — | ↗ |
| 2023-06-25 | Trizzino John | Officer | M-Exempt | A | Common Stock | 833 | 0.00 | — | 9,893 | — | ↗ |
| 2023-06-25 | Herrmann John A III | Officer | M-Exempt | A | Common Stock | 833 | 0.00 | — | 12,111 | — | ↗ |
| 2023-06-16 | Dubovsky Filip | Officer | M-Exempt | A | Common Stock | 4,155 | 8.04 | 33.4K | 47,065 | — | ↗ |
| 2023-06-12 | YOUNG JAMES F | Director | A-Award | A | Restricted Stock Units | 6,670 | 0.00 | — | 6,670 | — | ↗ |
| 2023-06-12 | Rodgers Richard J | Director | A-Award | A | Restricted Stock Units | 6,670 | 0.00 | — | 6,670 | — | ↗ |
| 2023-06-12 | MOTT DAVID M | Director | A-Award | A | Restricted Stock Units | 6,670 | 0.00 | — | 6,670 | — | ↗ |
| 2023-06-12 | MCGLYNN MARGARET G | Director | A-Award | A | Restricted Stock Units | 6,670 | 0.00 | — | 6,670 | — | ↗ |
| 2023-06-12 | King Rachel K. | Director | A-Award | A | Stock Option (Right to Buy) | 7,710 | 7.78 | 60.0K | 7,710 | — | ↗ |
| 2023-06-12 | DOUGLAS RICHARD | Director | A-Award | A | Stock Option (Right to Buy) | 7,710 | 7.78 | 60.0K | 7,710 | — | ↗ |
| 2023-06-12 | Alton Gregg H | Director | A-Award | A | Stock Option (Right to Buy) | 7,710 | 7.78 | 60.0K | 7,710 | — | ↗ |
| 2023-06-10 | YOUNG JAMES F | Director | M-Exempt | D | Restricted Stock Units | 4,600 | 0.00 | — | 0 | — | ↗ |
| 2023-06-10 | MOTT DAVID M | Director | M-Exempt | D | Restricted Stock Units | 3,100 | 0.00 | — | 0 | — | ↗ |
| 2023-06-10 | MCGLYNN MARGARET G | Director | M-Exempt | D | Restricted Stock Units | 3,100 | 0.00 | — | 0 | — | ↗ |
| 2023-06-10 | King Rachel K. | Director | M-Exempt | A | Common Stock | 3,100 | 0.00 | — | 10,050 | — | ↗ |
| 2023-06-10 | DOUGLAS RICHARD | Director | M-Exempt | D | Restricted Stock Units | 3,100 | 0.00 | — | 0 | — | ↗ |
| 2023-06-10 | Alton Gregg H | Director | M-Exempt | A | Common Stock | 3,100 | 0.00 | — | 3,800 | — | ↗ |
| 2023-03-10 | Trizzino John | Officer | F-InKind | D | Common Stock | 2,471 | 6.52 | 16.1K | 9,060 | — | ↗ |
| 2023-03-10 | Kelly James Patrick | Officer | M-Exempt | A | Common Stock | 4,609 | 6.52 | 30.1K | 5,832 | — | ↗ |
| 2023-03-10 | Herrmann John A III | Officer | M-Exempt | A | Common Stock | 4,609 | 6.52 | 30.1K | 13,058 | — | ↗ |
| 2023-03-10 | Glenn Gregory M | Officer | M-Exempt | D | Restricted Stock Units | 6,298 | 0.00 | — | 12,596 | — | ↗ |
| 2023-03-07 | Trizzino John | Officer | A-Award | A | Restricted Stock Units | 86,670 | 0.00 | — | 86,670 | — | ↗ |
| 2023-03-07 | Kelly James Patrick | Officer | A-Award | A | Restricted Stock Units | 36,670 | 0.00 | — | 36,670 | — | ↗ |
| 2023-03-07 | Herrmann John A III | Officer | A-Award | A | Restricted Stock Units | 38,330 | 0.00 | — | 38,330 | — | ↗ |
| 2023-03-07 | Glenn Gregory M | Officer | P-Purchase | A | Common Stock | 2,000 | 7.04 | 14.1K | 13,473 | — | ↗ |
| 2023-03-06 | Glenn Gregory M | Officer | P-Purchase | A | Common Stock | 3,000 | 7.48 | 22.5K | 11,473 | — | ↗ |
| 2023-03-01 | O'Hara Elaine | Officer | A-Award | A | Stock Option (Right to buy) | 67,900 | 6.86 | 465.8K | 67,900 | — | ↗ |
| 2023-01-23 | Jacobs John C | Officer | A-Award | A | Stock Option (Right to buy) | 290,700 | 0.00 | — | 290,700 | — | ↗ |
| 2022-12-14 | Trizzino John | Officer | M-Exempt | D | Restricted Stock Units | 1,600 | 0.00 | — | 1,600 | — | ↗ |
| 2022-12-14 | Herrmann John A III | Officer | M-Exempt | D | Restricted Stock Units | 2,100 | 0.00 | — | 2,100 | — | ↗ |
| 2022-12-14 | Glenn Gregory M | Officer | M-Exempt | A | Common Stock | 3,100 | 0.00 | — | 9,042 | — | ↗ |
| 2022-12-14 | Erck Stanley C | Officer | M-Exempt | D | Restricted Stock Units | 6,966 | 0.00 | — | 6,967 | — | ↗ |
| 2022-10-29 | Rodgers Richard J | Director | A-Award | A | Stock Option (Right to buy) | 17,095 | 0.00 | — | 17,095 | — | ↗ |
| 2022-09-26 | Erck Stanley C | Director / Officer | M-Exempt | A | Common Stock | 6,546 | 0.00 | — | 34,026 | — | ↗ |
| 2022-08-24 | Herrmann John A III | Officer | F-InKind | D | Common Stock | 772 | 37.07 | 28.6K | 2,975 | — | ↗ |
| 2022-08-19 | Trizzino John | Officer | F-InKind | D | Common Stock | 317 | 36.22 | 11.5K | 4,266 | — | ↗ |
| 2022-08-16 | Kelly James Patrick | Officer | M-Exempt | A | Common Stock | 2,367 | 0.00 | — | 2,367 | — | ↗ |
| 2022-06-25 | Trizzino John | Officer | F-InKind | D | Common Stock | 278 | 51.67 | 14.4K | 3,928 | — | ↗ |
| 2022-06-25 | Herrmann John A III | Officer | M-Exempt | A | Common Stock | 833 | 0.00 | — | 4,678 | — | ↗ |
| 2022-06-17 | YOUNG JAMES F | Director | M-Exempt | D | Restricted Stock Units | 1,400 | 0.00 | — | 0 | — | ↗ |
| 2022-06-17 | MOTT DAVID M | Director | M-Exempt | D | Restricted Stock Units | 700 | 0.00 | — | 0 | — | ↗ |
| 2022-06-17 | MCGLYNN MARGARET G | Director | M-Exempt | D | Restricted Stock Units | 700 | 0.00 | — | 0 | — | ↗ |
| 2022-06-17 | King Rachel K. | Director | M-Exempt | A | Common Stock | 700 | 0.00 | — | 6,950 | — | ↗ |
| 2022-06-17 | DOUGLAS RICHARD | Director | M-Exempt | A | Common Stock | 700 | 0.00 | — | 34,150 | — | ↗ |
| 2022-06-17 | Alton Gregg H | Director | M-Exempt | D | Restricted Stock Units | 700 | 0.00 | — | 0 | — | ↗ |
| 2022-06-16 | MCMANUS MICHAEL A JR | Director | M-Exempt | D | Restricted Stock Units | 700 | 0.00 | — | 0 | — | ↗ |
| 2022-06-10 | YOUNG JAMES F | Director | A-Award | A | Stock Option (Right to Buy) | 6,900 | 40.62 | 280.3K | 6,900 | — | ↗ |
| 2022-06-10 | MOTT DAVID M | Director | A-Award | A | Restricted Stock Units | 3,100 | 0.00 | — | 3,100 | — | ↗ |
| 2022-06-10 | MCGLYNN MARGARET G | Director | A-Award | A | Stock Option (Right to Buy) | 4,600 | 0.00 | — | 4,600 | — | ↗ |
| 2022-06-10 | King Rachel K. | Director | A-Award | A | Restricted Stock Units | 3,100 | 0.00 | — | 3,100 | — | ↗ |
| 2022-06-10 | DOUGLAS RICHARD | Director | A-Award | A | Restricted Stock Units | 3,100 | 0.00 | — | 3,100 | — | ↗ |
| 2022-06-10 | Alton Gregg H | Director | A-Award | A | Stock Option (Right to Buy) | 4,600 | 0.00 | — | 4,600 | — | ↗ |
| 2022-03-31 | YOUNG JAMES F | Director | S-Sale | D | Common Stock | 300 | 75.10 | 22.5K | 62,590 | — | ↗ |
| 2022-03-10 | Trizzino John | Officer | A-Award | A | Restricted Stock Units | 13,825 | 0.00 | — | 13,825 | — | ↗ |
| 2022-03-10 | Kelly James Patrick | Officer | A-Award | A | Stock Option (Right to Buy) | 20,737 | 77.77 | 1.61M | 20,737 | — | ↗ |
| 2022-03-10 | Herrmann John A III | Officer | A-Award | A | Restricted Stock Units | 13,825 | 0.00 | — | 13,825 | — | ↗ |
| 2022-03-10 | Glenn Gregory M | Officer | A-Award | A | Stock Option (Right to Buy) | 28,341 | 0.00 | — | 28,341 | — | ↗ |
| 2022-03-10 | Erck Stanley C | Officer | A-Award | A | Restricted Stock Units | 41,474 | 0.00 | — | 41,474 | — | ↗ |
| 2022-01-03 | Herrmann John A III | Officer | S-Sale | D | Common Stock | 997 | 139.08 | 138.7K | 7,048 | — | ↗ |
| 2021-12-31 | YOUNG JAMES F | Director | M-Exempt | A | Common Stock | 3,750 | 25.60 | 96.0K | 78,840 | — | ↗ |
| 2021-12-20 | Herrmann John A III | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 19.08 | 95.4K | 85,000 | — | ↗ |
| 2021-12-15 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 67 | 175.89 | 11.8K | 6,222 | — | ↗ |
| 2021-12-14 | Trizzino John | Officer | F-InKind | D | Common Stock | 773 | 168.43 | 130.2K | 3,373 | — | ↗ |
| 2021-12-14 | Herrmann John A III | Officer | M-Exempt | D | Restricted Stock Units | 2,100 | 0.00 | — | 4,200 | — | ↗ |
| 2021-12-14 | Glenn Gregory M | Officer | M-Exempt | A | Common Stock | 3,100 | 0.00 | — | 7,161 | — | ↗ |
| 2021-12-14 | Erck Stanley C | Director / Officer | M-Exempt | D | Restricted Stock Units | 6,967 | 0.00 | — | 13,933 | — | ↗ |
| 2021-12-13 | DOUGLAS RICHARD | Director | M-Exempt | A | Common Stock | 1,500 | 25.60 | 38.4K | 33,450 | — | ↗ |
| 2021-12-07 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 800 | 176.20 | 141.0K | 6,514 | — | ↗ |
| 2021-12-01 | Herrmann John A III | Officer | S-Sale | D | Common Stock | 943 | 196.11 | 184.9K | 4,426 | — | ↗ |
| 2021-11-30 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 678 | 199.25 | 135.1K | 10,068 | — | ↗ |
| 2021-11-29 | Herrmann John A III | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 19.08 | 95.4K | 95,000 | — | ↗ |
| 2021-11-26 | Glenn Gregory M | Officer | D-Return | D | Common Stock | 38 | 217.97 | 8.3K | 5,400 | — | ↗ |
| 2021-11-23 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 1,271 | 198.47 | 252.3K | 8,840 | — | ↗ |
| 2021-11-16 | Glenn Gregory M | Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,250 | 19.08 | 157.4K | 107,250 | — | ↗ |
| 2021-11-15 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 1,183 | 172.02 | 203.5K | 4,061 | — | ↗ |
| 2021-11-09 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 2,000 | 167.76 | 335.5K | 6,711 | — | ↗ |
| 2021-11-03 | Herrmann John A III | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 19.08 | 95.4K | 100,000 | — | ↗ |
| 2021-11-02 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 302 | 184.82 | 55.8K | 6,639 | — | ↗ |
| 2021-11-01 | Herrmann John A III | Officer | S-Sale | D | Common Stock | 100 | 162.69 | 16.3K | 5,017 | — | ↗ |
| 2021-10-29 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 353 | 148.99 | 52.6K | 4,103 | — | ↗ |
| 2021-10-26 | Glenn Gregory M | Officer | F-InKind | D | Common Stock | 637 | 134.99 | 86.0K | 4,741 | — | ↗ |
| 2021-10-19 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 1,400 | 164.85 | 230.8K | 8,027 | — | ↗ |
| 2021-10-15 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 1,183 | 170.00 | 201.1K | 4,061 | — | ↗ |
| 2021-10-12 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 2,900 | 162.45 | 471.1K | 8,411 | — | ↗ |
| 2021-10-05 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 600 | 175.32 | 105.2K | 6,640 | — | ↗ |
| 2021-10-04 | Erck Stanley C | Director / Officer | S-Sale | D | Common Stock | 4,700 | 176.48 | 829.4K | 45,132 | — | ↗ |
| 2021-10-01 | Herrmann John A III | Officer | S-Sale | D | Common Stock | 200 | 169.17 | 33.8K | 6,760 | — | ↗ |
| 2021-10-01 | Erck Stanley C | Director / Officer | S-Sale | D | Common Stock | 100 | 187.95 | 18.8K | 25,853 | — | ↗ |
| 2021-09-30 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 117 | 207.99 | 24.3K | 4,235 | — | ↗ |
| 2021-09-28 | Trizzino John | Officer | S-Sale | D | Common Stock | 312 | 208.46 | 65.0K | 4,931 | — | ↗ |
| 2021-09-27 | Trizzino John | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,501 | 19.08 | 143.1K | 102,501 | — | ↗ |
| 2021-09-27 | Glenn Gregory M | Officer | S-Sale | D | Common Stock | 95 | 248.13 | 23.6K | 4,061 | — | ↗ |
| 2021-09-26 | Trizzino John | Officer | F-InKind | D | Common Stock | 1,709 | 248.16 | 424.1K | 2,546 | — | ↗ |
| 2021-09-26 | Herrmann John A III | Officer | M-Exempt | A | Common Stock | 666 | 0.00 | — | 1,969 | — | ↗ |
| 2021-09-26 | Erck Stanley C | Director / Officer | M-Exempt | D | Restricted Stock Units | 6,546 | 0.00 | — | 6,546 | — | ↗ |
| 2021-09-23 | MOTT DAVID M | Director | S-Sale | D | Common Stock | 5,728 | 251.32 | 1.44M | 59,233 | — | ↗ |
| 2021-09-21 | Trizzino John | Officer | S-Sale | D | Common Stock | 853 | 228.22 | 194.7K | 3,327 | — | ↗ |
| 2021-09-20 | Trizzino John | Officer | S-Sale | D | Common Stock | 918 | 229.92 | 211.1K | 1,841 | — | ↗ |
| 2021-09-15 | Herrmann John A III | Officer | S-Sale | D | Common Stock | 262 | 234.90 | 61.5K | 706 | — | ↗ |
| 2021-09-15 | Glenn Gregory M | Officer | M-Exempt | D | Stock Option (Right to Buy) | 521 | 27.60 | 14.4K | 2,066 | — | ↗ |
Executive team
Top executives
EBIT / Employee
488.1K
Shares Outstanding
162.94M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | John C. Jacobs President and CEO | 792.9K | — | 3.55M | 3.76M | 640.3K | 114.0K | 8.86M | 82.53% | ↗ |
| 2 | 2025 | Elaine O'Hara EVP, Chief Strategy Officer | 561.1K | — | 1.33M | 1.41M | 288.1K | 97.8K | 3.69M | 74.32% | ↗ |
| 3 | 2025 | James P. Kelly EVP, Chief Financial Officer and Treasurer | 572.9K | — | 1.02M | 1.08M | 297.4K | 14.0K | 2.99M | 70.39% | ↗ |
| 4 | 2025 | Mark J. Casey, J.D. EVP, Chief Legal Officer and Corporate Secretary | 577.8K | — | 885.4K | 940.8K | 289.7K | 116.8K | 2.81M | 64.98% | ↗ |
| 5 | 2025 | Ruxandra Draghia-Akli, M.D., Ph.D. Former EVP, Head of Research & Development | 600.0K | — | 629.6K | 668.0K | 290.3K | 115.5K | 2.30M | 56.34% | ↗ |
| 6 | 2025 | John J. Trizzino Former President and Chief Operating Officer | 310.0K | — | 368.6K | 209.7K | — | 821.6K | 1.71M | 33.82% | ↗ |
| 7 | 2024 | John C. Jacobs President and CEO | 752.5K | — | 1.35M | 2.19M | 684.3K | 113.8K | 5.09M | 69.52% | ↗ |
| 8 | 2024 | James P. Kelly EVP, Chief Financial Officer and Treasurer | 545.9K | — | 948.6K | — | 321.2K | 13.7K | 1.83M | 51.85% | ↗ |
| 9 | 2024 | Elaine O'Hara EVP, Chief Strategy Officer | 535.6K | — | 646.8K | — | 358.2K | 97.6K | 1.64M | 39.48% | ↗ |
| 10 | 2024 | John J. Trizzino Former President and Chief Operating Officer | 582.8K | — | 776.2K | — | 261.9K | 12.5K | 1.63M | 47.52% | ↗ |
| 11 | 2024 | John J. Trizzino President and Chief Operating Officer | 582.8K | — | 776.2K | — | 261.9K | 12.5K | 1.63M | 47.52% | ↗ |
| 12 | 2024 | Filip Dubovsky, M.D. Former President, Research & Development | 336.3K | 250.0K | 776.2K | — | — | 192.0K | 1.55M | 49.93% | ↗ |
| 13 | 2024 | Mark J. Casey, J.D. EVP, Chief Legal Officer and Corporate Secretary | 558.3K | — | 64.7K | — | 319.6K | 119.8K | 1.06M | 6.09% | ↗ |
| 14 | 2023 | John C. Jacobs President and CEO | 662.9K | 250.0K | 2.98M | 3.00M | 236.3K | 149.0K | 7.27M | 82.14% | ↗ |
| 15 | 2023 | Stanley C. Erck Former President and CEO | 50.9K | — | — | 3.19M | — | 584.8K | 3.83M | 83.39% | ↗ |
| 16 | 2023 | Filip Dubovsky, M.D. President, Research & Development | 659.2K | — | 406.6K | 669.1K | 186.4K | 13.2K | 1.93M | 55.61% | ↗ |
| 17 | 2023 | Filip Dubovsky, M.D. Former President, Research & Development | 659.2K | — | 406.6K | 669.1K | 186.4K | 13.2K | 1.93M | 55.61% | ↗ |
| 18 | 2023 | John J. Trizzino Former President and Chief Operating Officer | 526.3K | — | 604.1K | 603.2K | 131.1K | 13.2K | 1.88M | 64.29% | ↗ |
| 19 | 2023 | John J. Trizzino President and Chief Operating Officer | 526.3K | — | 604.1K | 603.2K | 131.1K | 13.2K | 1.88M | 64.29% | ↗ |
| 20 | 2023 | Mark J. Casey, J.D. EVP, Chief Legal Officer and Corporate Secretary | 36.1K | 94.0K | 700.1K | 697.1K | — | 7.2K | 1.53M | 91.05% | ↗ |
| 21 | 2023 | Mark J. Casey EVP, Chief Legal Officer and Corporate Secretary | 36.1K | 94.0K | 700.1K | 697.1K | — | 7.2K | 1.53M | 91.05% | ↗ |
| 22 | 2023 | James P. Kelly EVP, Chief Financial Officer and Treasurer | 515.0K | — | 532.4K | 255.2K | 188.0K | 13.2K | 1.50M | 52.38% | ↗ |
| 23 | 2022 | Stanley C. Erck Former President and CEO | 749.8K | — | 3.23M | 4.09M | 305.9K | 34.7K | 8.40M | 87.02% | ↗ |
| 24 | 2022 | Gregory M. Glenn, M.D. Former President, Research and Development | 593.8K | — | 1.47M | 1.86M | 143.7K | 25.6K | 4.09M | 81.36% | ↗ |
| 25 | 2022 | James P. Kelly EVP, Chief Financial Officer and Treasurer | 508.8K | 100.0K | 1.08M | 1.36M | 123.4K | 12.2K | 3.18M | 76.60% | ↗ |
| 26 | 2022 | John A. Herrmann III, J.D. EVP, Chief Legal Officer and Corporate Secretary | 520.0K | — | 1.08M | 1.36M | 126.1K | 12.2K | 3.10M | 78.73% | ↗ |
| 27 | 2022 | John J. Trizzino President and Chief Operating Officer | 506.3K | — | 1.08M | 1.36M | 122.8K | 12.2K | 3.08M | 79.17% | ↗ |
| 28 | 2022 | John J. Trizzino EVP, Chief Commercial Officer and Chief Business Officer | 506.3K | — | 1.08M | 1.36M | 122.8K | 12.2K | 3.08M | 79.17% | ↗ |
| 29 | 2021 | James P. Kelly EVP, Chief Financial Officer and Treasurer | 183.8K | 100.0K | 1.63M | 2.94M | 68.2K | 3.3K | 4.93M | 92.79% | ↗ |
| 30 | 2021 | Stanley C. Erck Former President and CEO | 709.3K | — | — | — | 397.2K | 11.6K | 1.12M | 0.00% | ↗ |
| 31 | 2021 | Stanley C. Erck President and CEO | 709.3K | — | — | — | 397.2K | 11.6K | 1.12M | 0.00% | ↗ |
| 32 | 2021 | John J. Trizzino EVP, Chief Commercial Officer and Chief Business Officer | 456.3K | — | 427.3K | — | 169.4K | 11.2K | 1.06M | 40.16% | ↗ |
| 33 | 2021 | John J. Trizzino President and Chief Operating Officer | 456.3K | — | 427.3K | — | 169.4K | 11.2K | 1.06M | 40.16% | ↗ |
| 34 | 2021 | John J. Trizzino EVP, Chief Commercial | 456.3K | — | 427.3K | — | 169.4K | 11.2K | 1.06M | 40.16% | ↗ |
| 35 | 2021 | Gregory M. Glenn, M.D. President, Research and Development | 553.0K | — | — | — | 226.7K | 33.7K | 813.4K | 0.00% | ↗ |
| 36 | 2021 | Gregory M. Glenn, M.D. Former President, Research and Development | 553.0K | — | — | — | 226.7K | 33.7K | 813.4K | 0.00% | ↗ |
| 37 | 2021 | John A. Herrmann III, J.D. EVP, Chief Legal Officer and Corporate Secretary | 471.3K | — | — | — | 175.0K | 11.6K | 657.8K | 0.00% | ↗ |
| 38 | 2021 | Gregory F. Covino Former EVP, Chief Financial Officer and Treasurer | 210.1K | 22.0K | — | — | — | 38.5K | 270.7K | 0.00% | ↗ |
| 39 | 2020 | Stanley C. Erck President and CEO | 657.2K | — | 2.71M | 44.12M | 591.5K | 11.4K | 48.09M | 97.38% | ↗ |
| 40 | 2020 | Stanley C. Erck Former President and CEO | 657.2K | — | 2.71M | 44.12M | 591.5K | 11.4K | 48.09M | 97.38% | ↗ |
| 41 | 2020 | Gregory M. Glenn, M.D. Former President, Research and Development | 483.4K | — | 1.21M | 22.86M | 362.6K | 11.4K | 24.92M | 96.56% | ↗ |
| 42 | 2020 | Gregory M. Glenn, M.D. President, Research and Development | 483.4K | — | 1.21M | 22.86M | 362.6K | 11.4K | 24.92M | 96.56% | ↗ |
| 43 | 2020 | John J. Trizzino EVP, Chief Commercial Officer and Chief Business Officer | 415.9K | — | 831.4K | 19.82M | 249.5K | 11.4K | 21.33M | 96.83% | ↗ |
| 44 | 2020 | John J. Trizzino EVP, Chief Commercial | 415.9K | — | 831.4K | 19.82M | 249.5K | 11.4K | 21.33M | 96.83% | ↗ |
| 45 | 2020 | John J. Trizzino EVP, Chief Commercial Officer, Chief Business Officer and Interim Chief Financial Officer | 415.9K | — | 831.4K | 19.82M | 249.5K | 11.4K | 21.33M | 96.83% | ↗ |
| 46 | 2020 | John A. Herrmann III EVP, Chief Legal Officer and Corporate Secretary | 402.8K | — | 1.03M | 18.92M | 241.7K | 11.4K | 20.61M | 96.82% | ↗ |
| 47 | 2020 | John A. Herrmann III, J.D. EVP, Chief Legal Officer and Corporate Secretary | 402.8K | — | 1.03M | 18.92M | 241.7K | 11.4K | 20.61M | 96.82% | ↗ |
| 48 | 2020 | Gregory F. Covino Former EVP, Chief Financial Officer and Treasurer | 55.0K | — | 661.7K | 660.0K | 33.0K | 8.0K | 1.42M | 93.22% | ↗ |
| 49 | 2019 | Stanley C. Erck President and CEO | 642.7K | — | 431.6K | 986.7K | 366.4K | 11.2K | 2.44M | 58.16% | ↗ |
| 50 | 2019 | Gregory M. Glenn, M.D. President, Research and Development | 470.5K | — | 348.3K | 819.4K | 225.8K | 11.2K | 1.88M | 62.27% | ↗ |
| 51 | 2019 | John J. Trizzino EVP, Chief Commercial | 390.7K | — | 330.8K | 584.1K | 150.4K | 9.5K | 1.47M | 62.43% | ↗ |
| 52 | 2019 | John J. Trizzino SVP, Chief Business Officer and CFO and Treasurer | 390.7K | — | 330.8K | 584.1K | 150.4K | 9.5K | 1.47M | 62.43% | ↗ |
| 53 | 2019 | John J. Trizzino EVP, Chief Commercial Officer, Chief Business Officer and Interim Chief Financial Officer | 390.7K | — | 330.8K | 584.1K | 150.4K | 9.5K | 1.47M | 62.43% | ↗ |
| 54 | 2019 | John A. Herrmann III, J.D. EVP, Chief Legal Officer and Corporate Secretary | 378.6K | — | 329.5K | 488.4K | 145.8K | 11.2K | 1.35M | 60.43% | ↗ |
| 55 | 2019 | John A. Herrmann III SVP, General Counsel and Corporate Secretary | 378.6K | — | 329.5K | 488.4K | 145.8K | 11.2K | 1.35M | 60.43% | ↗ |
| 56 | 2019 | John A. Herrmann III EVP, Chief Legal Officer and Corporate Secretary | 378.6K | — | 329.5K | 488.4K | 145.8K | 11.2K | 1.35M | 60.43% | ↗ |
| 57 | 2018 | Stanley C. Erck President and CEO | 638.0K | — | — | 3.51M | — | 11.0K | 4.16M | 84.39% | ↗ |
| 58 | 2018 | Gregory M. Glenn, M.D. President, Research and Development | 460.1K | — | — | 1.13M | 79.1K | 11.0K | 1.68M | 67.27% | ↗ |
| 59 | 2018 | John J. Trizzino SVP, Chief Business Officer and CFO and Treasurer | 378.1K | — | — | 890.7K | 53.5K | 7.5K | 1.33M | 66.98% | ↗ |
| 60 | 2018 | John J. Trizzino EVP, Chief Commercial Officer, Chief Business Officer and Interim Chief Financial Officer | 378.1K | — | — | 890.7K | 53.5K | 7.5K | 1.33M | 66.98% | ↗ |
| 61 | 2018 | John A. Herrmann III EVP, Chief Legal Officer and Corporate Secretary | 362.7K | — | — | 712.6K | 51.3K | 11.0K | 1.14M | 62.64% | ↗ |
| 62 | 2018 | John A. Herrmann III SVP, General Counsel and Corporate Secretary | 362.7K | — | — | 712.6K | 51.3K | 11.0K | 1.14M | 62.64% | ↗ |
| 63 | 2017 | Stanley C. Erck President, CEO and Interim CFO | 624.0K | — | — | 1.75M | 383.8K | 10.8K | 2.77M | 63.25% | ↗ |
| 64 | 2017 | Stanley C. Erck President and CEO | 624.0K | — | — | 1.75M | 383.8K | 10.8K | 2.77M | 63.25% | ↗ |
| 65 | 2017 | Gregory M. Glenn, M.D. President, Research and Development | 450.0K | — | — | 531.3K | 229.5K | 10.5K | 1.22M | 43.50% | ↗ |
| 66 | 2017 | John J. Trizzino SVP, Chief Business Officer and CFO and Treasurer | 366.1K | — | — | 425.0K | 149.1K | 7.5K | 947.7K | 44.84% | ↗ |
| 67 | 2017 | John J. Trizzino SVP, Commercial Operations | 366.1K | — | — | 425.0K | 149.1K | 7.5K | 947.7K | 44.84% | ↗ |
| 68 | 2017 | John A. Herrmann III SVP, General Counsel and Corporate Secretary | 340.0K | — | — | 425.0K | 138.6K | 9.8K | 913.3K | 46.53% | ↗ |
| 69 | 2017 | Barclay A. Phillips Former SVP, CFO and Treasurer | 316.3K | — | — | — | — | 40.6K | 356.8K | 0.00% | ↗ |
| 70 | 2016 | Stanley C. Erck President and CEO | 618.0K | — | — | 3.25M | — | 7.4K | 3.88M | 83.87% | ↗ |
| 71 | 2016 | Stanley C. Erck President, CEO and Interim CFO | 618.0K | — | — | 3.25M | — | 7.4K | 3.88M | 83.87% | ↗ |
| 72 | 2016 | Gregory M. Glenn, M.D. President, Research and Development | 441.3K | — | — | 1.19M | — | 7.5K | 1.64M | 72.68% | ↗ |
| 73 | 2016 | Barclay A. Phillips SVP, Chief Financial Officer and Treasurer | 363.3K | — | — | 790.3K | — | 7.5K | 1.16M | 68.07% | ↗ |
| 74 | 2016 | Barclay A. Phillips Former SVP, CFO and Treasurer | 363.3K | — | — | 790.3K | — | 7.5K | 1.16M | 68.07% | ↗ |
| 75 | 2016 | John J. Trizzino SVP, Commercial Operations | 359.5K | — | — | 790.3K | — | 7.4K | 1.16M | 68.30% | ↗ |
| 76 | 2016 | John J. Trizzino SVP, Chief Business Officer and CFO and Treasurer | 359.5K | — | — | 790.3K | — | 7.4K | 1.16M | 68.30% | ↗ |
| 77 | 2016 | John A. Herrmann III SVP, General Counsel and Corporate Secretary | 335.0K | — | — | 790.3K | — | 7.5K | 1.13M | 69.77% | ↗ |
| 78 | 2015 | Stanley C. Erck President and CEO | 575.0K | — | — | 3.92M | 345.0K | 7.8K | 4.85M | 80.88% | ↗ |
| 79 | 2015 | Stanley C. Erck President, CEO and Interim CFO | 575.0K | — | — | 3.92M | 345.0K | 7.8K | 4.85M | 80.88% | ↗ |
| 80 | 2015 | Gregory M. Glenn, M.D. President, Research and Development | 410.0K | — | — | 1.31M | 143.5K | 10.5K | 1.87M | 69.87% | ↗ |
| 81 | 2015 | Barclay A. Phillips SVP, Chief Financial Officer and Treasurer | 351.3K | — | — | 872.0K | 122.9K | 6.5K | 1.35M | 64.46% | ↗ |
| 82 | 2015 | Barclay A. Phillips Former SVP, CFO and Treasurer | 351.3K | — | — | 872.0K | 122.9K | 6.5K | 1.35M | 64.46% | ↗ |
| 83 | 2015 | John J. Trizzino SVP, Commercial Operations | 335.0K | — | — | 872.0K | 117.3K | 8.1K | 1.33M | 65.45% | ↗ |
| 84 | 2015 | John A. Herrmann III SVP, General Counsel and Corporate Secretary | 315.0K | — | — | 872.0K | 110.3K | 6.8K | 1.30M | 66.87% | ↗ |
| 85 | 2014 | Stanley C. Erck President and CEO | 487.8K | — | — | 2.28M | 304.8K | 7.7K | 3.08M | 74.03% | ↗ |
| 86 | 2014 | Stanley C. Erck President CEO | 487.8K | — | — | 2.28M | 304.8K | 7.7K | 3.08M | 74.03% | ↗ |
| 87 | 2014 | John J. Trizzino SVP, Commercial Operations | 247.8K | — | — | 738.8K | 110.6K | 4.0K | 1.10M | 67.09% | ↗ |
| 88 | 2014 | Gregory M. Glenn, M.D. SVP, Research and Development | 389.8K | — | — | 443.5K | 165.1K | 9.9K | 1.01M | 43.99% | ↗ |
| 89 | 2014 | Gregory M. Glenn, M.D. President, Research and Development | 389.8K | — | — | 443.5K | 165.1K | 9.9K | 1.01M | 43.99% | ↗ |
| 90 | 2014 | John A. Herrmann III SVP, General Counsel and Corporate Secretary | 280.5K | — | — | 477.2K | 120.0K | 7.3K | 884.9K | 53.92% | ↗ |
| 91 | 2014 | Barclay A. Phillips SVP, Chief Financial Officer and Treasurer | 330.0K | — | — | 380.1K | 139.8K | 5.5K | 855.4K | 44.44% | ↗ |
| 92 | 2014 | Barclay A. Phillips SVP, Chief Financial Officer Treasurer | 330.0K | — | — | 380.1K | 139.8K | 5.5K | 855.4K | 44.44% | ↗ |
| 93 | 2014 | Russell P. Wilson SVP, Business Development | 326.6K | — | — | 380.1K | 138.3K | 5.3K | 850.3K | 44.71% | ↗ |
| 94 | 2014 | Timothy J. Hahn, Ph.D. SVP, Global Manufacturing Operations | 291.7K | — | — | 316.8K | 122.5K | 7.5K | 738.5K | 42.90% | ↗ |
| 95 | 2013 | Stanley C. Erck President and CEO | 448.3K | — | 900.0K | — | 239.1K | 8.0K | 1.60M | 56.42% | ↗ |
| 96 | 2013 | Stanley C. Erck President CEO | 448.3K | — | — | 900.0K | 239.1K | 8.0K | 1.60M | 56.42% | ↗ |
| 97 | 2013 | Stanley C. Erck President CEO | 448.3K | — | — | 900.0K | 239.1K | 8.0K | 1.60M | 56.42% | ↗ |
| 98 | 2013 | Gregory M. Glenn, M.D. President, Research and Development | 371.9K | — | 150.0K | — | 137.1K | 6.9K | 665.9K | 22.53% | ↗ |
| 99 | 2013 | Gregory M. Glenn, M.D. SVP Chief Medical Officer | 371.9K | — | — | 150.0K | 137.1K | 6.9K | 665.9K | 22.53% | ↗ |
| 100 | 2013 | Gregory M. Glenn, M.D. SVP, Research and Development | 371.9K | — | — | 150.0K | 137.1K | 6.9K | 665.9K | 22.53% | ↗ |
| 101 | 2013 | Russell P. Wilson SVP, Business Development | 317.3K | — | — | 150.0K | 117.0K | 8.5K | 592.9K | 25.30% | ↗ |
| 102 | 2013 | Russell P. Wilson SVP, Business Development | 317.3K | — | — | 150.0K | 117.0K | 8.5K | 592.9K | 25.30% | ↗ |
| 103 | 2013 | Timothy J. Hahn, Ph.D. SVP, Manufacturing and Process Development | 284.5K | — | — | 150.0K | 99.9K | 6.4K | 540.8K | 27.74% | ↗ |
| 104 | 2013 | Timothy J. Hahn, Ph.D. SVP, Global Manufacturing Operations | 284.5K | — | — | 150.0K | 99.9K | 6.4K | 540.8K | 27.74% | ↗ |
| 105 | 2013 | Barclay A. Phillips SVP, Chief Financial Officer and Treasurer | 156.3K | — | 263.3K | — | 57.6K | 4.3K | 481.6K | 54.68% | ↗ |
| 106 | 2013 | John A. Herrmann III SVP, General Counsel and Corporate Secretary | 229.3K | — | 150.0K | — | 84.7K | 4.6K | 468.6K | 32.01% | ↗ |
| 107 | 2013 | Barclay A. Phillips SVP, Chief Financial Officer Treasurer | 156.3K | — | — | 263.3K | 57.6K | 4.3K | 418.6K | 62.90% | ↗ |
| 108 | 2013 | Barclay A. Phillips SVP, Chief Financial Officer Treasurer | 156.3K | — | — | 263.3K | 57.6K | 4.3K | 418.6K | 62.90% | ↗ |
| 109 | 2013 | Frederick W. Driscoll Former, VP, Chief Financial Officer Treasurer | 115.5K | — | — | 150.0K | — | 46.4K | 312.0K | 48.08% | ↗ |
| 110 | 2012 | Stanley C. Erck President CEO | 430.0K | — | — | 613.0K | 198.0K | 1.4K | 1.24M | 49.34% | ↗ |
| 111 | 2012 | Stanley C. Erck President CEO | 430.0K | — | — | 613.0K | 198.0K | 1.4K | 1.24M | 49.34% | ↗ |
| 112 | 2012 | Gregory M. Glenn, M.D. SVP Chief Medical Officer | 362.3K | — | — | 102.2K | 116.7K | 2.0K | 583.2K | 17.52% | ↗ |
| 113 | 2012 | Gregory M. Glenn, M.D. SVP Chief Medical Officer | 362.3K | — | — | 102.2K | 116.7K | 2.0K | 583.2K | 17.52% | ↗ |
| 114 | 2012 | Gregory M. Glenn, M.D. SVP, Research and Development | 362.3K | — | — | 102.2K | 116.7K | 2.0K | 583.2K | 17.52% | ↗ |
| 115 | 2012 | Frederick W. Driscoll VP, Chief Financial Officer Treasurer | 296.6K | — | — | 102.2K | 95.5K | 2.5K | 496.8K | 20.56% | ↗ |
| 116 | 2012 | Frederick W. Driscoll Former, VP, Chief Financial Officer Treasurer | 296.6K | — | — | 102.2K | 95.5K | 2.5K | 496.8K | 20.56% | ↗ |
| 117 | 2012 | Timothy J. Hahn, Ph.D. SVP, Global Manufacturing Operations | 278.2K | — | — | 102.2K | 89.6K | — | 469.9K | 21.74% | ↗ |
| 118 | 2012 | Timothy J. Hahn, Ph.D. SVP, Manufacturing and Process Development | 278.2K | — | — | 102.2K | 89.6K | — | 469.9K | 21.74% | ↗ |
| 119 | 2012 | Russell P. Wilson SVP, Business Development | 311.1K | — | — | 17.0K | 100.2K | 3.6K | 431.9K | 3.94% | ↗ |
| 120 | 2012 | Russell P. Wilson SVP, Business Development | 311.1K | — | — | 17.0K | 100.2K | 3.6K | 431.9K | 3.94% | ↗ |
| 121 | 2012 | Barclay A. Phillips SVP, Chief Financial Officer Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 122 | 2011 | Stanley C. Erck President CEO | 370.4K | — | — | 905.8K | 138.9K | 1.2K | 1.42M | 63.95% | ↗ |
| 123 | 2011 | Stanley C. Erck President CEO | 370.4K | — | — | — | 138.9K | 1.2K | 1.42M | 0.00% | ↗ |
| 124 | 2011 | Rahul Singhvi, Sc.D. Former President CEO | 136.1K | — | — | 342.6K | — | 761.5K | 1.24M | 27.63% | ↗ |
| 125 | 2011 | Frederick W. Driscoll Former, VP, Chief Financial Officer Treasurer | 287.3K | — | — | 205.6K | 80.4K | 2.6K | 575.9K | 35.69% | ↗ |
| 126 | 2011 | Frederick W. Driscoll VP, Chief Financial Officer Treasurer | 287.3K | — | — | 205.6K | 80.4K | 2.6K | 575.9K | 35.69% | ↗ |
| 127 | 2011 | Frederick W. Driscoll VP, Chief Financial Officer Treasurer | 287.3K | — | — | 205.6K | 80.4K | 2.6K | 575.9K | 35.69% | ↗ |
| 128 | 2011 | Gregory M. Glenn, M.D. SVP Chief Medical Officer | 353.3K | — | — | 87.7K | 98.9K | 3.2K | 543.1K | 16.15% | ↗ |
| 129 | 2011 | Gregory M. Glenn, M.D. SVP Chief Medical Officer | 353.3K | — | — | 87.7K | 98.9K | 3.2K | 543.1K | 16.15% | ↗ |
| 130 | 2011 | Gregory M. Glenn, M.D. SVP Chief Medical Officer | 353.3K | — | — | 87.7K | 98.9K | 3.2K | 543.1K | 16.15% | ↗ |
| 131 | 2011 | Russell P. Wilson SVP, Business Development | 49.2K | 58.3K | 69.5K | — | 13.8K | — | 389.3K | 17.85% | ↗ |
| 132 | 2011 | Russell P. Wilson SVP, Business Development | 49.2K | 58.3K | 69.5K | 198.6K | 13.8K | — | 389.3K | 68.85% | ↗ |
| 133 | 2011 | John Trizzino Former SVP, Business Development | 213.5K | — | — | 137.0K | — | 18.9K | 369.4K | 37.09% | ↗ |
| 134 | 2011 | Timothy J. Hahn, Ph.D. SVP, Manufacturing and Process Development | 142.3K | — | — | 156.5K | 39.9K | — | 338.7K | 46.21% | ↗ |
| 135 | 2011 | Timothy J. Hahn, Ph.D. SVP, Manufacturing and Process Development | 142.3K | — | — | 156.5K | 39.9K | — | 338.7K | 46.21% | ↗ |
| 136 | 2011 | Barclay A. Phillips SVP, Chief Financial Officer Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 137 | 2010 | Rahul Singhvi, Sc.D. President Chief Executive Officer | 450.2K | — | — | 234.8K | 206.1K | 96.3K | 987.4K | 23.78% | ↗ |
| 138 | 2010 | Rahul Singhvi, Sc.D. Former President CEO | 450.2K | — | — | 234.8K | 206.1K | 95.7K | 986.8K | 23.79% | ↗ |
| 139 | 2010 | Stanley C. Erck Executive Chairman of the Board of Directors | 263.7K | — | — | 479.5K | 201.2K | 5.0K | 949.4K | 50.51% | ↗ |
| 140 | 2010 | Stanley C. Erck President CEO | 263.7K | — | — | 479.5K | 201.2K | 2.7K | 947.1K | 50.63% | ↗ |
| 141 | 2010 | Gregory Glenn, M.D. Senior Vice President Chief Medical Officer | 175.0K | 75.0K | 105.5K | 494.9K | 49.7K | 2.0K | 902.1K | 66.55% | ↗ |
| 142 | 2010 | Gregory M. Glenn, M.D. SVP Chief Medical Officer | 175.0K | 75.0K | 105.5K | 494.9K | 49.7K | 1.2K | 901.3K | 66.61% | ↗ |
| 143 | 2010 | Gregory M. Glenn, M.D. SVP Chief Medical Officer | 175.0K | 75.0K | 105.5K | 494.9K | 49.7K | 1.2K | 901.3K | 66.61% | ↗ |
| 144 | 2010 | John Trizzino SVP, Business Development | 288.9K | — | — | 156.5K | 82.1K | 926.00 | 528.5K | 29.62% | ↗ |
| 145 | 2010 | John Trizzino Former SVP, Business Development | 288.9K | — | — | 156.5K | 82.1K | — | 527.5K | 29.67% | ↗ |
| 146 | 2010 | Frederick W. Driscoll VP, Chief Financial OfficerTreasurer | 277.9K | — | — | 99.9K | 84.5K | 4.8K | 467.2K | 21.39% | ↗ |
| 147 | 2010 | Frederick W. Driscoll VP, Chief Financial Officer Treasurer | 277.9K | — | — | 99.9K | 84.5K | 2.1K | 464.5K | 21.51% | ↗ |
| 148 | 2010 | Frederick W. Driscoll VP, Chief Financial Officer Treasurer | 277.9K | — | — | 99.9K | 84.5K | 2.1K | 464.5K | 21.51% | ↗ |
| 149 | 2009 | Frederick W. Driscoll VP, Chief Financial OfficerTreasurer | 98.0K | — | 52.1K | 733.7K | 34.7K | 677.00 | 919.2K | 85.49% | ↗ |
| 150 | 2009 | Frederick W. Driscoll VP, Chief Financial Officer Treasurer | 98.0K | — | 52.1K | 733.7K | 34.7K | — | 918.5K | 85.56% | ↗ |
| 151 | 2009 | Rahul Singhvi, Sc.D. President Chief Executive Officer | 434.1K | — | — | 68.3K | 100.0K | 2.8K | 605.3K | 11.29% | ↗ |
| 152 | 2009 | Rahul Singhvi, Sc.D. Former President CEO | 434.1K | — | — | 68.3K | 100.0K | 2.4K | 604.9K | 11.30% | ↗ |
| 153 | 2009 | John Trizzino SVP, Business Development | 130.6K | — | — | 425.3K | 46.2K | 443.00 | 602.6K | 70.58% | ↗ |
| 154 | 2009 | John Trizzino Former SVP, Business Development | 130.6K | — | — | 425.3K | 46.2K | — | 602.1K | 70.63% | ↗ |
| 155 | 2009 | Thomas S. Johnston VP, Strategy | 214.6K | 50.0K | — | 23.4K | 75.9K | 3.6K | 367.5K | 6.38% | ↗ |
| 156 | 2009 | Penny M. Heaton, M.D. Former VP Chief Medical Officer | 261.6K | — | — | 29.3K | — | 39.1K | 330.1K | 8.87% | ↗ |
| 157 | 2009 | Raymond J. Hage Former SVP of Commercial Operations | 255.9K | — | — | 23.4K | — | 438.00 | 279.7K | 8.38% | ↗ |
| 158 | 2009 | James Robinson Former VP of Technical Quality Control Operations | 241.3K | — | — | 29.3K | — | 3.8K | 274.5K | 10.67% | ↗ |
| 159 | 2009 | Evdoxia E. Kopsidas Former Senior Director of Finance Principal Accounting Officer | 177.2K | — | — | 11.6K | — | 25.2K | 214.0K | 5.44% | ↗ |
| 160 | 2009 | Len Stigliano Former VP, Treasurer Chief Financial Officer | 21.6K | — | — | — | — | 7.4K | 29.0K | 0.00% | ↗ |
| 161 | 2008 | Rahul Singhvi, ScD., MBA President Chief Executive Officer | 406.3K | — | 100.2K | — | — | 3.8K | 707.7K | 14.16% | ↗ |
| 162 | 2008 | Rahul Singhvi, Sc.D. President Chief Executive Officer | 406.3K | — | — | 262.8K | — | 3.8K | 672.9K | 39.06% | ↗ |
| 163 | 2008 | Penny M. Heaton VP Chief Medical Officer | 285.4K | — | 34.3K | — | — | 18.3K | 549.4K | 6.25% | ↗ |
| 164 | 2008 | Len Stigliano VP, Treasurer Chief Financial Officer | 257.0K | — | — | — | — | 37.0K | 489.1K | 0.00% | ↗ |
| 165 | 2008 | Penny M. Heaton, M.D. Former VP Chief Medical Officer | 285.4K | — | — | 112.6K | — | 18.3K | 416.3K | 27.06% | ↗ |
| 166 | 2008 | James Robinson VP of Technical Quality Control | 232.1K | — | 32.3K | — | — | 3.5K | 405.7K | 7.97% | ↗ |
| 167 | 2008 | Raymond J. Hage SVP of Commercial Operations | 247.3K | — | 16.3K | — | — | 569.00 | 404.0K | 4.05% | ↗ |
| 168 | 2008 | Len Stigliano Former VP, Treasurer Chief Financial Officer | 257.0K | — | — | 48.8K | — | 37.0K | 342.8K | 14.24% | ↗ |
| 169 | 2008 | Raymond J. Hage Former SVP of Commercial Operations | 247.3K | — | — | 90.1K | — | 569.00 | 338.0K | 26.66% | ↗ |
| 170 | 2008 | James Robinson Former VP of Technical Quality Control Operations | 232.1K | — | — | 56.3K | — | 3.5K | 292.0K | 19.29% | ↗ |
| 171 | 2007 | Rahul Singhvi, ScD.,MBA President Chief Executive Officer | 350.0K | — | 124.2K | — | 332.5K | 66.3K | 1.03M | 12.07% | ↗ |
| 172 | 2007 | Rahul Singhvi, ScD., MBA President Chief Executive Officer | 350.0K | — | 124.2K | — | 332.5K | 66.3K | 1.03M | 12.07% | ↗ |
| 173 | 2007 | Rahul Singhvi, Sc.D. President Chief Executive Officer | 350.0K | — | — | 206.0K | 332.5K | 66.3K | 954.9K | 21.58% | ↗ |
| 174 | 2007 | Len Stigliano Former VP, Treasurer Chief Financial Officer | 182.0K | 7.2K | — | 500.8K | 72.7K | 21.8K | 784.5K | 63.84% | ↗ |
| 175 | 2007 | James Robinson Former VP of Technical Quality Control Operations | 176.7K | — | 97.0K | 329.6K | 67.9K | 2.6K | 673.8K | 63.31% | ↗ |
| 176 | 2007 | Penny M. Heaton VP Chief Medical Officer | 261.7K | — | 34.3K | — | 99.1K | 44.1K | 606.8K | 5.66% | ↗ |
| 177 | 2007 | Raymond J. Hage Former SVP of Commercial Operations | 235.6K | — | — | 154.5K | 87.7K | 24.4K | 502.2K | 30.77% | ↗ |
| 178 | 2007 | Raymond J. Hage SVP of Commercial Operations | 235.6K | — | 35.2K | — | 87.7K | 24.4K | 494.9K | 7.11% | ↗ |
| 179 | 2007 | Penny M. Heaton, M.D. Former VP Chief Medical Officer | 261.7K | — | — | 82.4K | 99.1K | 44.1K | 487.3K | 16.91% | ↗ |
| 180 | 2007 | James Robinson VP of Technical Quality Control Operations | 176.7K | — | 29.9K | — | 67.9K | 2.6K | 348.7K | 8.58% | ↗ |
| 181 | 2007 | James Robinson VP of Technical Quality Control | 176.7K | — | 29.9K | — | 67.9K | 2.6K | 348.7K | 8.58% | ↗ |
| 182 | 2007 | Len Stigliano VP, Treasurer Chief Financial Officer | 182.0K | 7.2K | — | — | 72.7K | 21.8K | 313.4K | 0.00% | ↗ |
| 183 | 2007 | Jeffrey Church Former VP, Treasurer, Secretary and CFO | 88.5K | — | — | — | — | 322.00 | 29.0K | 0.00% | ↗ |
| 184 | 2006 | Rahul Singhvi, Sc.D., M.B.A. | — | — | — | — | — | — | 1.17M | 0.00% | ↗ |
| 185 | 2006 | Rahul Singhvi, ScD.,MBA President Chief Executive Officer | 337.5K | — | 117.8K | — | 100.0K | 117.4K | 1.00M | 11.73% | ↗ |
| 186 | 2006 | Rahul Singhvi, ScD., MBA President Chief Executive Officer | 337.5K | — | 117.8K | — | 100.0K | 117.4K | 1.00M | 11.73% | ↗ |
| 187 | 2006 | Raymond J. Hage, Jr. | — | — | — | — | — | — | 640.2K | 0.00% | ↗ |
| 188 | 2006 | Stephen I. Bandak | — | — | — | — | — | — | 494.7K | 0.00% | ↗ |
| 189 | 2006 | Gale E. Smith, Ph.D. | — | — | — | — | — | — | 489.3K | 0.00% | ↗ |
| 190 | 2006 | Raymond J. Hage SVP of Commercial Operations | 225.3K | — | 35.2K | — | 81.1K | 2.6K | 472.9K | 7.44% | ↗ |
| 191 | 2006 | Rick A. Bright, Ph.D. | — | — | — | — | — | — | 374.1K | 0.00% | ↗ |
| 192 | 2006 | Dennis W. Genge Vice President, Treasurer and Chief Financial Officer | — | — | — | — | — | — | 344.1K | 0.00% | ↗ |
| 193 | 2006 | Jeffrey W. Church | — | — | — | — | — | — | 224.2K | 0.00% | ↗ |
| 194 | 2006 | Patricia Hall | — | — | — | — | — | — | 189.1K | 0.00% | ↗ |
| 195 | 2006 | Jeffrey Church Former VP, Treasurer, Secretary and CFO | 79.9K | 10.0K | 11.5K | — | 23.0K | — | 172.7K | 6.64% | ↗ |
| 196 | 2006 | Penny M. Heaton VP Chief Medical Officer | 58.7K | — | 8.6K | — | 19.0K | — | 111.5K | 7.70% | ↗ |
| 197 | 2006 | Len Stigliano VP, Treasurer Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 198 | 2006 | James Robinson VP of Technical Quality Control Operations | — | — | — | — | — | — | — | — | ↗ |
| 199 | 2005 | Rahul Singhvi President and Chief Executive Officer | 245.8K | 180.0K | — | — | — | — | 425.8K | 0.00% | ↗ |
| 200 | 2005 | Raymond J. Hage, Jr Senior Vice President and Chief Operating Officer | 195.0K | 58.5K | — | — | — | — | 253.5K | 0.00% | ↗ |
| 201 | 2005 | Nelson M. Sims Former President and Chief Executive Officer | 241.7K | — | — | — | — | — | 241.7K | 0.00% | ↗ |
| 202 | 2005 | Dennis W. Genge Vice President, Treasurer and Chief Financial Officer | 181.0K | 47.0K | — | — | — | — | 228.0K | 0.00% | ↗ |
| 203 | 2005 | Denis M. O’Donnell, M.D. Former Chairman of the Board of Directors | 63.5K | — | — | — | — | — | 63.5K | 0.00% | ↗ |
| 204 | 2004 | Nelson M. Sims President and Chief Executive Officer | 400.0K | — | — | — | — | 41.2K | 441.2K | 0.00% | ↗ |
| 205 | 2004 | Nelson M. Sims Former President and Chief Executive Officer | 400.0K | — | — | — | — | — | 400.0K | 0.00% | ↗ |
| 206 | 2004 | D. Craig Wright, M.D. Chief Scientific Officer | 254.2K | — | — | — | — | 2.5K | 256.8K | 0.00% | ↗ |
| 207 | 2004 | Ford R. Lynch Senior Vice President Sales and Marketing | 220.0K | — | — | — | — | 29.5K | 249.5K | 0.00% | ↗ |
| 208 | 2004 | Raymond J. Hage, Jr Senior Vice President and Chief Operating Officer | 188.7K | — | — | — | — | — | 188.7K | 0.00% | ↗ |
| 209 | 2004 | Dennis W. Genge Vice President, Treasurer and Chief Financial Officer | 178.7K | — | — | — | — | — | 178.7K | 0.00% | ↗ |
| 210 | 2004 | Rahul Singhvi President and Chief Executive Officer | 147.8K | — | — | — | — | — | 147.8K | 0.00% | ↗ |
| 211 | 2004 | Denis M. O’Donnell, M.D. Chairman of the Board of Directors | 125.0K | — | — | — | — | 741.00 | 125.7K | 0.00% | ↗ |
| 212 | 2004 | Denis M. O’Donnell, M.D. Former Chairman of the Board of Directors | 125.0K | — | — | — | — | — | 125.0K | 0.00% | ↗ |
| 213 | 2003 | D. Craig Wright, M.D. Chief Scientific Officer | 248.4K | 62.7K | — | — | — | 1.7K | 312.9K | 0.00% | ↗ |
| 214 | 2003 | D. Craig Wright, M.D. Chief Scientific Officer | 248.4K | 62.7K | — | — | — | — | 311.1K | 0.00% | ↗ |
| 215 | 2003 | Dennis W. Genge Vice President, Treasurer and Chief Financial Officer | 171.6K | 75.2K | — | — | — | — | 246.8K | 0.00% | ↗ |
| 216 | 2003 | Dennis W. Genge Vice President, Treasurer and Chief Financial Officer | 171.6K | 75.2K | — | — | — | — | 246.8K | 0.00% | ↗ |
| 217 | 2003 | Mitchell J. Kelly | 202.3K | — | — | — | — | — | 202.3K | 0.00% | ↗ |
| 218 | 2003 | Ann P. McGeehan | 173.7K | 7.4K | — | — | — | — | 181.1K | 0.00% | ↗ |
| 219 | 2003 | Nelson M. Sims President and Chief Executive Officer | 157.7K | — | — | — | — | — | 157.7K | 0.00% | ↗ |
| 220 | 2003 | Nelson M. Sims President and Chief Executive Officer | 157.7K | — | — | — | — | — | 157.7K | 0.00% | ↗ |
| 221 | 2003 | Nelson M. Sims Former President and Chief Executive Officer | 157.7K | — | — | — | — | — | 157.7K | 0.00% | ↗ |
| 222 | 2003 | Denis M. O’Donnell, M.D. Chairman of the Board of Directors | 125.0K | — | — | — | — | 414.00 | 125.4K | 0.00% | ↗ |
| 223 | 2003 | Denis M. O’Donnell, M.D. Former Chairman of the Board of Directors | 125.0K | — | — | — | — | — | 125.0K | 0.00% | ↗ |
| 224 | 2003 | Denis M. O’Donnell, M.D. Former Chairman of the Board of Directors | 125.0K | — | — | — | — | — | 125.0K | 0.00% | ↗ |
| 225 | 2003 | Ford R. Lynch Senior Vice President Sales and Marketing | 55.0K | 12.4K | — | — | — | — | 67.4K | 0.00% | ↗ |
| 226 | 2003 | Ford R. Lynch Senior Vice President Sales and Marketing | 55.0K | 12.4K | — | — | — | — | 67.4K | 0.00% | ↗ |
| 227 | 2003 | Rahul Singhvi President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 228 | 2003 | Raymond J. Hage, Jr Senior Vice President and Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 229 | 2002 | John A. Spears | 305.3K | — | — | — | — | — | 305.3K | 0.00% | ↗ |
| 230 | 2002 | Dennis W. Genge Vice President, Treasurer and Chief Financial Officer | 165.0K | 75.0K | — | — | — | 2.4K | 242.4K | 0.00% | ↗ |
| 231 | 2002 | Marvin A. Heuer, M.D | 191.0K | 50.0K | — | — | — | — | 241.0K | 0.00% | ↗ |
| 232 | 2002 | Dennis W. Genge Vice President, Treasurer and Chief Financial Officer | 165.0K | 75.0K | — | — | — | — | 240.0K | 0.00% | ↗ |
| 233 | 2002 | D. Craig Wright, M.D. Chief Scientific Officer | 225.9K | 11.2K | — | — | — | 2.3K | 239.4K | 0.00% | ↗ |
| 234 | 2002 | D. Craig Wright, M.D. Chief Scientific Officer | 225.9K | 11.2K | — | — | — | — | 237.1K | 0.00% | ↗ |
| 235 | 2002 | James R. Mirto | 234.3K | — | — | — | — | — | 234.3K | 0.00% | ↗ |
| 236 | 2002 | Ann P. McGeehan | 169.0K | 52.5K | — | — | — | — | 221.5K | 0.00% | ↗ |
| 237 | 2002 | Denis M. O’Donnell, M.D. Chairman of the Board of Directors | 125.0K | — | — | — | — | 213.00 | 125.2K | 0.00% | ↗ |
| 238 | 2002 | Denis M. O’Donnell, M.D. Former Chairman of the Board of Directors | 125.0K | — | — | — | — | — | 125.0K | 0.00% | ↗ |
| 239 | 2002 | Mitchell J. Kelly | 112.5K | — | — | — | — | — | 112.5K | 0.00% | ↗ |
| 240 | 2002 | Ford R. Lynch Senior Vice President Sales and Marketing | — | — | — | — | — | — | — | — | ↗ |
| 241 | 2002 | Nelson M. Sims President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 242 | 2001 | John A. Spears | 266.8K | 250.0K | — | — | — | — | 516.8K | 0.00% | ↗ |
| 243 | 2001 | James R. Mirto | 210.2K | 75.0K | — | — | — | — | 285.2K | 0.00% | ↗ |
| 244 | 2001 | D. Craig Wright, M.D. Chief Scientific Officer | 204.1K | 56.7K | — | — | — | — | 260.8K | 0.00% | ↗ |
| 245 | 2001 | Dennis W. Genge Vice President, Treasurer and Chief Financial Officer | 159.7K | 50.0K | — | — | — | — | 209.7K | 0.00% | ↗ |
| 246 | 2001 | Denis M. O’Donnell, M.D. Former Chairman of the Board of Directors | 125.0K | — | — | — | — | — | 125.0K | 0.00% | ↗ |
| 247 | 2000 | John A. Spears | 250.0K | 200.0K | — | — | — | — | 450.0K | 0.00% | ↗ |
| 248 | 2000 | D. Craig Wright, M.D. Chief Scientific Officer | 190.0K | 35.9K | — | — | — | — | 225.9K | 0.00% | ↗ |
| 249 | 2000 | Donald J. MacPhee | 125.0K | 7.5K | — | — | — | — | 132.5K | 0.00% | ↗ |
| 250 | 2000 | James R. Mirto | 129.6K | — | — | — | — | — | 129.6K | 0.00% | ↗ |
| 251 | 2000 | Denis O’Donnell, M.D. | 125.0K | — | — | — | — | — | 125.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John Charles Jacobs | President, Chief Executive Officer & Director | 2M | male |
| Mark Casey | Executive Vice President, Chief Legal Officer & Corporate Secretary | 984.3K | male |
| Elaine O'Hara | Executive Vice President & Chief Strategy Officer | 947.0K | female |
| James Patrick Kelly | Executive Vice President, Chief Financial Officer & Treasurer | 884.3K | male |
| Richard Crowley | Executive Vice President & Chief Operating Officer | — | male |
| Robert Walker | EVice President and Head of Research & Development | — | — |
| Silvia Taylor | Executive Vice President, Chief Corporate Affairs Officer & Head of Novavax Sweden | — | female |
| Troy Morgan | Senior Vice President, Deputy General Counsel & Chief Compliance Officer | — | male |
| Erika S. Trahan | Associate Director of Investor & Public Relations | — | female |
| Ian J. Watkins | Executive Vice President & Chief Human Resources Officer | — | male |
| Luis Sanay | Vice President of Investor Relations | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NVAX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
